Lipid membrane destabilization induced by amyloid-beta peptide in the systems mimicking preclinical Alzheimer's disease

S. A. Kurakin*[ID][1], O. I. Ivankov[ID][1], T. N. Murugova[ID][1], D. R. Badreeva[ID][1],
E. B. Dushanov[ID][1,2], E. V. Ermakova[ID][1], A. I. Kuklin[ID][1,3], and N. Kučerka†[ID][1,4]

[1]*Joint Institute for Nuclear Research, Dubna, Russia*
[2]*Department of Biophysics, Dubna State University, Dubna, Russia*
[3]*Moscow Institute of Physics and Technology, Dolgoprudny, Russia*
[4]*Faculty of Pharmacy, Comenius University Bratislava, Bratislava, Slovakia*

Abstract

The amyloid-beta peptide (Aβ peptide) is proposed to play a central role in the onset of Alzheimer's disease (AD). The pathology is associated with the fast accumulation of neurotoxic amyloid aggregates in brain tissues, though the fundamentals of the disease's progression remain unsolved. It is noted that the preclinical stage of AD may play a crucial role in its further irreversible development. Namely, interactions between lipid membranes and Aβ-peptide molecules incorporated therein at relatively low concentrations should be under a close attention. In this review, we discuss recent works devoted to studying the lipid–peptide interactions with a specific focus on the lipid membrane reorganizations caused by Aβ(25–35) peptide in the preclinical AD mimicking conditions. The interactions observed are believed to be important in understanding the mechanisms of the Aβ-peptide destructive effects on lipid membranes and the corresponding onset of the disease. The methods of applied nuclear physics have proven remarkably relevant in such research. The scattering methods provided instrumental information on a level of supramolecular assemblies, while spectrometry allowed obtaining information on the molecular level. Finally, molecular dynamics simulations provided details unachievable by experimental approaches, though the validation role of the latter cannot be undermined. Altogether, the recent advances in research results prove these complementary approaches the most appropriate for tackling the complex issues of biomembrane interactions.

Keywords: Alzheimer's disease, amyloid-beta peptide, lipid membrane, structure, dynamics

1. Amyloid hypothesis in Alzheimer's disease

Alzheimer's disease (AD) is a devastating neurodegenerative brain pathology manifested by the loss of neuron cells. AD is becoming a major problem for public health, since the disease

---

*Corresponding author e-mail address: `Sergej.Kurakin@nf.jinr.ru`
†Corresponding author e-mail address: `kucerka@nf.jinr.ru`

is known to be the most common cause of dementia characterized by speech and memory disorders, impairment of cognitive and physical abilities [1]. Since aging plays a considerable role in the development of AD, the disease is an inalienable attribute of all countries in the 21st century. AD will manifest itself in the future especially often due to an increase in the human average life expectancy. For example, it was estimated that about 24 million people in the world suffered from AD in 2005, which was less than 0.4% of the world's population [2], whereas this number will increase to 131 million people by 2050 ($\sim 1.35\%$ of the population estimated). Notwithstanding that AD was first discovered more than a century ago, in 1906, the foundations of the AD progression elude unambiguous explanations to the present days.

There are several hypotheses for the onset of AD, such as cholinergic hypothesis, tau hypothesis, and amyloid hypothesis, to name but those most accepted [3–5]. One of the most recognized scenarios is an amyloid cascade hypothesis introduced in 1991 [5, 6]. The Aβ peptide in its two isoforms 1–40 and 1–42 is presumed among the most possible causes of AD. Specifically, Aβ peptides form extracellular oligomers leading further to irreversible accumulation of large aggregates in the form of insoluble amyloid fibrils and plaques, which have been the hallmarks of AD from its very discovery. Recent advancements in the cryo-electron microscopy allowed determining structures of Aβ fibrils at the atomistic and supramolecular levels [7–12]. The studies are unified by the conclusion that amyloid fibrils consist of large elongated and twisted stacks of Aβ peptide exhibiting cross-β sheet conformation. However, a comprehensive understanding of the relation between a structure of fibrils and their functional role in AD has not been fully achieved.

Neurotoxicity of Aβ peptides has been attributed not only to their fibrillar forms. In 1998, the Aβ oligomer hypothesis was proposed [13]. It is based on the discovery that insoluble amyloid oligomers consisting of Aβ peptides are central nervous system neurotoxins that destruct particular synapses. This causes a selective nerve cell death leading to the onset of AD. Notwithstanding that the oligomers usually escaped a main focus of clinical trials, which are aimed mostly at the attempts to combat formation of amyloid fibrils, it is accepted nowadays that the oligomers are the most neurotoxic Aβ-peptide form becoming thus a potential target in the fight against AD [14–16].

Further, many investigations of Aβ peptide, including those under the primary focus of this review, are aimed at the studies of monomeric form of the peptide in cell lipid membranes, rather than insoluble amyloid fibrils and oligomers. The approach is substantiated by the emergence of Aβ peptides in the lipid membranes of brain cells at the preclinical AD stage. Specifically, the Aβ peptides are known to be cleaved enzymatically (by means of β- and γ-secretase) from amyloid precursor protein (APP), which plays substantial physiological functions in the central nervous systems [17]. After the cleavage, Aβ peptides are able to accumulate and aggregate either in the membrane or outside lipid environment (Figure 1).

The Aβ(25–35) peptide fragment (residues 25–35) consisting of 11 amino acids was also identified to form neurotoxic amyloid oligomers and fibrils. This Aβ peptide has been found in the brain of patients who suffered from AD. It is believed to be a result of processing the full-length Aβ peptide by proteases [20]. The Aβ(25–35) and its aggregates were documented to damage neurons, inhibit DNA-dependent protein kinase activity, lead to transcription dysregulations and decrease Ca^{2+}-ATPase activity [20–25]. Moreover, this peptide fragment is a transmembrane segment of APP that initially interacts with a lipid membrane of cells [26]. The peptide being a part of APP contains hydrophilic residues situated in the extracellular environment (25–28), whereas the transmembrane part containing 29–35 residues is hydrophobic (Figure 2) [27]. Under *in vitro* conditions, the Aβ(25–35) peptides reproduce the main

Figure 1. The sketch representing amyloidogenic cleavage of amyloid precursor protein (APP) into Aβ peptide by enzymes of β- and γ-secretase. The monomers of resulting Aβ peptides may be involved either in their aggregation in extracellular environment or in membrane destabilization upon their interactions directly with lipid membrane. Both ways lead to peptide cytotoxicity. Graphics is adapted from [18, 19].

$$H_2N-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH$$

$$25 \quad 26 \quad 27 \quad 28 \quad 29 \quad 30 \quad 31 \quad 32 \quad 33 \quad 34 \quad 35$$

a

b

Figure 2. The nucleic acids sequence of the Aβ(25–35) peptide (*a*) and its chemical structure (*b*).

properties of full-length Aβ peptide. For example, molecules of Aβ(25–35) form aggregates that sediment in solution within several hours depending on the environment [28, 29]. Thus, Aβ(25–35) may serve as a convenient tool to study molecular mechanisms causing AD.

The Aβ-peptide interactions with lipid membranes under *in vitro* conditions have been investigated quite extensively in recent years. Namely, researchers study the membrane structures, peptide conformations and peptide localization in membranes in connection with the development of many neurodegenerative diseases [30]. After all, the lipid bilayer as a main component of cell membranes plays an important role in the defense against the aggressive factors of outer

environment and provides plenty of functions essential for cell activity. There are studies that indicate capability of Aβ peptides to damage lipid membranes via three mechanisms of action proposed as models of membrane destruction [31]. The mechanisms include a) membrane destabilization by prefibrillar peptide units (so-called carpet model), b) formation of transmembrane amyloid pores that can function as ion channels, and c) membrane damage by peptide monomers or oligomers that are able to extract lipids from the membrane (detergent-like interactions). All these processes violate the integrity of membranes and their normal function. Interestingly, there is evidence for the presence of lipids in amyloid fibrils found in brain tissues of patients with AD, suggesting a possible direct link between fibril growth and involvement of lipids [32]. Therefore, understanding the lipid–peptide interactions is a necessary step in the studies that reveal the role of the mentioned processes in the AD pathogenesis.

The lipid–peptide interactions depend on temperature that also defines a thermodynamic state of lipid membranes. In turn, various membrane-active molecules (such as cholesterol and melatonin), metal ions from intracellular and extracellular environment, and membrane proteins determine lipid–peptide interactions. Altogether, these factors affect structural organization of lipid membranes and regulate their dynamic properties [33–39]. Tuning up the structure and dynamics of lipid membranes by temperature and different biologically relevant additives is assumed one of the ways to prevent the neurotoxic effects of Aβ peptides on the lipid membrane.

Due to the compositional complexity of cell membranes, it is convenient to study artificially prepared model membrane systems, e.g., spherical lipid vesicles, which mimic the main distinctive features of the bilayered membrane structure [40]. Moreover, it is important to examine membranes that contain the various lipid species of interest in order to gain insights into the roles of individual lipid components in lipid–peptide interactions. The membrane composition of brain and its compartments is unique in a high concentration of total lipids ($\approx 50\%$ of the dry weight of brain is the lipid mass [41]) and in a content of lipid fractions. Among widespread lipids, there are phospholipids that include phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and cardiolipin [42]. Intriguingly, the overwhelming majority of all phospholipids in different brain compartments are represented by PC and PE [43].

PCs are well-known species of lipids ubiquitous in brain tissues and potentially participating in the onset of AD [43, 44]. There are PC lipids differing by hydrocarbon chain length and the number of carbon double bonds, such as 1,2-dimyristoyl-sn-3-phosphatidylcholine (DMPC, 14:0), 1,2-dipalmitoyl-sn3-phosphatidylcholine (DPPC, 16:0), 1,2-palmitoyloleoyl-sn-3-phosphatidylcholine (POPC, 16:0-18:1), to name but those most relevant. DMPC and DPPC are fully saturated phospholipids, while POPC is a monounsaturated phospholipid. While brain phospholipids, when compared to other organs, are known to be highly enriched in polyunsaturated fatty acids, DPPC usually takes the first or second place in abundance amongst PCs [43–45]. The relative number of different types of lipids has been reported to change in brain tissues affected with AD [43–47]. Moreover, disturbances of the content of saturated lipids in brain were directly attributed to the risk of AD [47].

There are studies that propose considerable roles of lipid rafts in the AD development. The lipid rafts are mobile membrane microdomains that are highly enriched with cholesterol and sphingolipids, whereas differing from surrounding lipids [48]. The rafts form a liquid-ordered phase with lipids being more ordered and tightly packed. The heterogeneous separation of membranes provided by lipid rafts leads to changes in the dynamic and structural properties of lipids and surrounding membrane molecules. The importance of lipid rafts in Aβ-peptide aggregation, neurotoxicity, and the onset of AD has been reviewed recently [49–51]. For in-

stance, more liquid-ordered rafts were found in patients with AD compared to those found in a control group. In addition, the observation brings attention to the variations in membrane lipid composition that can change with aging, thus linking it to the AD risk [52–54]. The lipid composition of membranes, along with their phase separation, is therefore an integral part of the amyloid hypothesis in AD, as it ultimately influences the pathways that promote the AD development as well as those with a normal function.

It is noteworthy that a close focus on Aβ peptides is also relevant from a therapeutical point of view. The molecular processes occurring within peptides under different conditions serve as a basis for the development of drugs that are introduced into clinical trials of patients suffering from AD. The trials are rich in the synthesis, modification, and adaptation of new promising anti-Aβ medicine aimed against formation of amyloid deposits [55]. However, the findings have not been completely translated to clinical practice because of prevailing inefficiency of the drugs designed. Nevertheless, some approaches for fighting the Aβ toxicity emerged in recent years. The examples include immunotherapy approaches, such as development of anti-Aβ monoclonal antibodies, adoptive therapy with Aβ specific regulatory T cells, and Aβ vaccines [56–59]. Intriguingly, a progress in nanotechnology also provides perspectives in designing nanoparticles that have a tunable chemical composition and strong specificity towards amyloid deposits. The nanoparticles are able to bind to peptides and therefore could be possible candidates for the treatment of the disease in the future [60, 61].

2. Interactions of Aβ(25–35) with lipid membranes

The studies of lipid–peptide interactions are primarily the tasks of *in vitro* investigations of model lipid systems. In such approaches, low-resolution physical methods are indispensable. For instance, small-angle neutron and X-ray scattering (SANS and SAXS correspondingly) and diffraction, and solid-state nuclear magnetic resonance (NMR), Raman and circular dichroism (CD) spectroscopies are among the most informative research techniques [62] They serve as a foundation for solving internal and overall structures of lipid membranes and proteins at various scale levels. In addition, the limits of existing experimental approaches may often be extended further by computational methods. Molecular dynamics (MD) simulations are able to complement many new details to the overall picture of the lipid membrane structures and protein conformations.

The physical methods have been utilized in the studies examining the interactions of Aβ peptides with model membranes composed of various lipids. The translational dynamics of lipid membranes including DMPC/DMPS (DMPS — 1,2-dimyristoyl-sn-3-phosphatidylserine) mixtures was studied upon the addition of Aβ(25–35) to the oriented lipid membranes [63, 64]. It was found that the Aβ peptides accelerate the lateral self-diffusion of lipids, which indicates that lipids are more disordered and destabilized in the presence of peptide molecules. Similar membrane-destabilizing behavior was also found for the full-length peptide Aβ(1–42). Namely, Dante and colleagues [65] studied the ability of Aβ(1–42) to interact with unilamellar vesicles whose membrane was formed by a mixture of POPC/POPS (1,2-palmitoyloleoyl-sn-3-phosphatidylserine). It was found that Aβ(1–42) was readily incorporated into the membrane, while disordering the lipids. At the same time, the dynamics of Aβ(25–35) molecules was studied during their interaction with micelles that served as model membranes. It is noted that the part of the Aβ(25–35) peptide containing residues 25–27 is highly ordered and less dynamic, while the region of residues 28–35 is disordered [66].

The localization of Aβ(25–35) peptide molecules in membranes is not always clearly defined and it strongly depends on many factors. They mostly include the lipid and charge composition

of the membrane, external conditions, as well as sample preparation protocol. For example, Mason and colleagues [67] showed that Aβ(25–35) is mainly localized in the hydrophobic part of the membrane with a predominant predisposition of the charged N-terminus (25–28) near the head groups of phospholipids in a membrane composed of POPC. Similar results were obtained by Dante and coworkers for a POPC/POPS lipid mixture [68]. Also, it was revealed that the lipid composition mainly affects the localization of the hydrophobic part of the peptide. The C-terminal fragment of the peptide enters the membrane at different depths (6 Å or 14 Å from the center of the bilayer along the normal to the membrane in the case of a system without and with PSs, respectively) depending on the POPC/POPS lipid ratio. In addition, it was reported that the peptide strongly disorders lipids, increasing the membrane fluidity. Computer simulations [69] revealed two stable states in which Aβ(25–35) peptide can be found in the lipid membrane: near the surface of the DMPC lipid bilayer with a predominant inclination of the N-terminus inside the membrane, and a state in which the peptide is relatively deeply localized in the membrane. There are studies of electrostatic interactions of the Aβ(25–35) peptide with a membrane composed of a mixture of POPC/POPG (POPG — 1,2-palmitoyloleoyl-sn-3-phosphatidylglycerol) [70]. Namely, attraction of the positively charged part of the peptide to the lipid head groups of anionic lipids has been found. It allows the peptide molecules to be situated closer to the membrane–water interface. In the case of a mixture of saturated lipids (DMPC/DMPS), Dies et al. [71] found the Aβ(25–35) peptides being either incorporated into the membrane or in membrane-bound state. Ermilova et al. [72] reported that the degree of Aβ(25–35) incorporation into lipid bilayers depends on the saturation of lipid chains. The peptide is prone to situate near the hydrophilic region in the membrane made of unsaturated lipids, while it resides on the surface of the bilayer made of saturated phospholipids and tends to aggregate. The influence of lipid saturation on peptide localization is anticipated, since acyl chain unsaturation perturbs hydrocarbon chain region, resulting in increased chain disorder. Lau and colleagues [73] concluded that the localization of Aβ(25–35) peptide in the membrane also depends on the sample preparation procedure. While Aβ(25–35) molecules reside closer to the hydrophobic part of the lipid bilayer in the case of the membrane that contains peptides incorporated during the sample preparation, the peptides are prone to adsorb onto membrane surface in the case of the peptide addition to the solution of vesicles. Also, Aβ(25–35) molecules were reported to demonstrate spontaneous membrane insertion from water environment, thus confirming the ability of Aβ(25–35) to strongly interact with lipid bilayers [74]. Consequently, despite the fact that many studies have revealed two preferred localizations of the Aβ(25–35) peptide in membranes, the location of the peptide is hard to predict for a particular system.

There are observations of a tendency of Aβ(25–35) peptides to aggregate in lipid membranes. It has been suggested that the Aβ(25–35)–membrane interactions occur in three stages: adsorption of peptides from surroundings, nucleation of aggregates, and their penetration into membranes [75]. In addition, it was shown that the monomeric form of the peptide has a trend to form insoluble large structures in DMPC and DOPC (1,2-dioleoyl-sn-3-phosphatidylcholine) lipid bilayers [76]. Some data described accelerated formation of peptide clusters representing β-sheet secondary structures inside membranes consisting of a mixture of POPC and DMPC (or DMPS) lipids [77, 78]. The number of aggregates significantly increased at relatively high concentrations of the peptide (> 10 mol%, where mol% is the peptide/lipid molar fraction), while the size of the clusters did not depend on its amount. A characteristic feature of such aggregates was a significant discrepancy between the hydrophobic thicknesses of peptides and the lipid bilayers that led to local distortions of the membrane structure and disordering of lipids near the peptides. The studies on Aβ(25–35)–membrane interactions have also shown

ion-conducting pore formation by the peptide [79, 80]. While some results proposed a model of membrane pores formed by Aβ(25–35) peptides having α-helical secondary structure [81], other data revealed that the Aβ(25–35) peptide incorporated into membrane forms 6- or 8-stranded β-barrel-like structures [82]. The β-barrel-like structure provides an inner cavity of 6–7 Å radius, where Aβ(25–35) secondary structures are represented significantly by β sheets that penetrate the lipid membrane consisting of POPC/POPG. These channels conduct calcium ions that can disrupt their homeostasis, and therefore they are considered toxic.

3. Morphological reorganization of lipid membranes triggered by Aβ(25–35)

Although a significant amount of literature is dedicated to the studies of interactions between Aβ peptides and lipid membranes, it is important to scrutinize the general structural organization of lipid membranes in solution when interacting with Aβ(25–35) peptides. SAXS and SANS may come to the rescue providing valuable insights into shapes of lipid aggregates (i.e., their morphology, such as a sphere or a disc) and revealing the structural parameters of lipid bilayers. The methods provide small-angle scattering curves that depict intensities I of a scattered beam as a function of scattering vector q. The resulted curves may be fitted by using model-based approaches to extract quantitative values of membrane structural parameters. The length scales probed by small-angle scattering methods range from 1 to over 100 nm, which is relevant to the dimensions of both the membrane and overall vesicle. Therefore, the vesicle radius (R) and membrane thickness (d_L or d_{HH} obtained from SANS and SAXS, respectively [83]) as the most useful parameters describing the overall structure of lipid objects may be calculated from the analysis of small-angle scattering curves. The information about vesicle size is contained in the low-q region of the curves, where the scattering is sensitive to large length scales (i.e., according to the relation $q = 2\pi/d$, where d is a characteristic dimension), while the information about bilayer structure lies in the mid- and high-q regions.

SANS and SAXS methods have detected the changes in membrane morphology in the lipid vesicles composed of saturated DPPC or DMPC lipids and Aβ(25–35) peptides incorporated into membranes at relatively low peptide concentrations (<5 mol%). Such systems mimic the preclinical AD stage. Namely, a reorganization of unilamellar vesicles (ULVs) into discoidal structures and small unilamellar vesicles (SUVs) has been observed (Figure 3a) thanks to distinct features of the SANS (and SAXS) curves in the low-q region in the case of different lipid morphologies (ULVs, discs and SUVs) (Figure 3b) [84]. Initial ULVs were obtained via an extrusion through polycarbonate filters with pores of 500 Å diameter [85, 86]. The ULV radius was ≈ 350 Å [84]. The radii of emerging discs and SUVs were estimated to be around 200 and 150 Å, respectively. Such reorganizations of membrane general shape happened during the main phase transition temperature (T_m) of lipids when heating and cooling the samples through T_m and only in the presence of the Aβ(25–35) peptides embedded in the lipid bilayer. Along with transformations in membrane morphology, parallel changes in the membrane thickness have been detected. The changes were comparable to those observed upon phase transitions of lipid membranes (without Aβ(25–35)), thus confirming the phase transition of membranes in the presence of Aβ(25–35) [84].

The abrupt changes in the membrane morphologies when crossing T_m were interpreted as an Aβ(25–35)-triggered destabilization of membranes and a consequent reorganization of their supramolecular structure [84]. It should be emphasized that lipid membranes do not get damaged, rather they break and convert their shape between states stable at different thermodynamic phases. Reorganizations between different lipid morphologies (e.g., disc–vesicle or disc–micelle transitions) are known to be observed in mixtures of short-chain and long-chain

Figure 3. *a*) Sketch of morphological reorganizations of lipid membranes consisting of saturated lipids (DPPC or DMPC) triggered by $A\beta(25\text{–}35)$ peptide monomers incorporated into lipid bilayers. Having been unaffected upon heating from the gel phase to the fluid phase through the main phase transition temperature (T_m) of lipids (1), unilamellar vesicles (ULVs) undergo an irreversible reorganization to discs upon subsequent cooling (2). Upon further heating and cooling through T_m, there are reversible reorganizations between the discs (below T_m) and small unilamellar vesicles (SUVs) (above T_m) (3). *b*) SANS curves (symbols) and their best fits (lines) for DPPC+$A\beta(25\text{–}35)$ samples in the temperature range of 20–50°C. The small-q region of the curves displays the features inherent to different morphologies of the lipid objects investigated (ULVs, discs, or SUVs). The figure is adapted from [87].

lipids [88, 89], upon addition of various surfactants, detergents [90–93], and peptides [94–99], such as melittin — a membrane lytic peptide. In most cases, the effects of reorganizations occur near T_m and are known to be dependent on molecular composition and outer environment, whereas the peptides themselves are frequently capable of disrupting lipid membranes. Several mechanisms of antimicrobial peptide actions have been proposed, including formation of toroidal pores penetrating a membrane and extraction of lipids from a membrane by peptide molecules [100]. It has also been presumed that $A\beta$ and antimicrobial peptides share similar molecular mechanisms leading to lipid membrane destabilizations [101, 102].

The changes in the membrane structure and dynamics during the phase transition may be a foundation to a temporary membrane breakage. A typical feature of the phase transition of lipid membranes containing a single type of saturated lipids is a sharp jump in membrane characteristics. It is indicated by a change in the lateral lipid diffusion rate, ordering of lipid hydrocarbon chains, head group hydration, and intermolecular entropy [103]. Membrane thermodynamic phase transitions upon gradual heating include the lipid pretransition (identified by pretransition temperature T_p) from the gel to ripple phase with subsequent main transition (T_m) to the fluid phase [104, 105]. The gel phase of membranes is distinguished by highly ordered lipids, in contrary to the disordered fluid state [104]. The ripple phase is known to form sawtooth-like membrane surface with alternation of two areas containing more ordered and disordered lipids [106, 107], though the recent studies suggested more complex ripple phase structure involving several different lipid conformations [108, 109]. During the phase transitions upon heating, a lipid membrane switches between the less diffusive form and the more diffusive fluid state that may influence lipid–peptide interactions, including those responsible for membrane destabilization.

In addition to the lipid structural properties, an Aβ-peptide secondary structure, which is also known to vary significantly in different membrane thermodynamic phases, may contribute to the membrane destabilization. It was found that Aβ peptides undertake α-helix, random coil, and β-sheet structures in different membrane environments. For instance, Yoda et al. previously reported that full-length Aβ-peptide secondary structures were able to change between all the mentioned types, when the lipid membrane was crossing various thermodynamic states during its heating [110].

The transition of Aβ peptides from more disordered random coils to ordered α-helices was concluded to be important in the case of fibril formation, since the emergence of α-helices have been considered as an intermediate key step in the formation of Aβ fibrils containing β sheets [111, 112]. It is known that not only a full-length Aβ peptide but its fragments, Aβ(25–35) in particular, may adopt α-helix in the presence of a zwitterionic lipid bilayer [113–115]. Such transitions are apparently caused by the hydrophobic interactions between Aβ-peptide molecules and lipid chains [116]. On the one hand, the emergence of β-sheet conformations of Aβ peptides is associated with fibrillogenesis [117]. On the other hand, the lipid environment is known to affect the secondary structure of membrane-active peptides that eventually leads to the disruptions of the bilayer integrity [118].

Given a crucial contribution of Aβ(25–35) peptides to the membrane destabilization when crossing T_m, the secondary structures of Aβ(25–35) peptides incorporated in the discs and SUVs have been an object of close attention. Recent results obtained by using circular dichroism spectroscopy, Raman spectroscopy, and molecular dynamics simulations displayed secondary structures represented predominantly by random coils ($\approx 50\%$), while changing little when reorganizing between discs and SUVs (being in the gel and fluid phase, respectively) [87]. The data indicated that the secondary structure of Aβ(25–35) does not influence the morphology of the lipid objects, just as the thermodynamic state of the lipid membrane does not affect the Aβ(25–35) secondary structure.

Notwithstanding neuronal toxicity of Aβ peptides, it is known that Aβ peptide may participate in important physiological functions. There are studies reviewed in [119] that describe possible roles of Aβ peptides in protection against some forms of cancer, regulation of activity at hippocampal synapses, and emergence of antimicrobial properties. It is worth noting that the peptides should only be regarded as toxic when their production is excessive, and aggregation is imbalanced. While normal Aβ-peptide concentration range lies in picomolar and nanomolar intervals [120, 121], elevated peptide concentrations were reported to cause, for example, a rapid Aβ-peptide aggregation into cross-β sheets, which strongly disturb the lipid bilayer [77]. Therefore, the effect of higher Aβ-peptide concentrations on the morphological reorganizations from ULVs into discs and SUVs has also been scrutinized [87]. The effect has been studied in the extended concentration range of the micromolar (relative to water) interval. Interestingly, but not unexpectedly, morphological reorganizations were observed only above a specific concentration of Aβ(25–35) molecules ($\geqslant 1$ mol%) incorporated into the lipid membranes [87]. Namely, the ULVs containing various concentrations of Aβ(25–35) peptides incorporated in DPPC membrane were subjected to heating–cooling cycles in order to launch the chain of Aβ(25–35)-driven morphological reorganization. Comparing the values of radius R of initial ULVs (Figure 3, empty symbols) obtained by SAXS measurements with those of the final-state samples (ULVs or discs) after heating–cooling cycles (Figure 4, full dots), one may notice a critical peptide concentration, above which morphological reorganization is observed. This effect may be well related to the recognized AD pathogenesis that resulted from an excessive accumulation of Aβ peptides in brain tissues of AD patients. Further, the importance of

Figure 4. Radii (R) of ULVs at 0.01–0.5 mol% of Aβ(25–35) and radii of discs at 1–5 mol% of Aβ(25–35) in DPPC+Aβ(25–35) systems after heating–cooling cycles of ULVs (full dots). For the clarity of presentation, empty dots display the same samples before heating–cooling cycles. All R values were obtained at $T = 20°$C in the DPPC gel phase. The drop of R values at 1–5 mol% of Aβ(25–35) indicates the ULVs-to-discs reorganization after heating–cooling cycles performed on initial ULVs. The circled group of points describes the R values of discoidal objects. The results were taken from [87].

critical concentration of Aβ peptides was emphasized by *in vitro* experiments, when increasing the concentrations of full-length Aβ peptides in lipid supported bilayers. The peptides led to the disruption of lipid membranes via lipid extraction and formation of holes [122, 123]. Hence, the morphological reorganization of ULVs that happens when crossing T_m is a direct evidence of peptide–lipid interactions playing a key role in the membrane breakage when reaching a certain peptide concentration.

4. Lipid–peptide arrangements in discoidal structures and unilamellar vesicles

When searching for the mechanisms of the lipid membrane reorganization triggered by the disruptive effects of Aβ(25–35) peptides, it is increasingly important to study the lipid–peptide arrangements in the membrane objects formed. A wide variety of membrane proteins and peptides induce membrane curvature and change their closest lipid environment for a specific purpose [124, 125]. For example, clathrin, a membrane protein involved in the transport processes of substances, performs an important function by concentrating epsins that contribute to membrane deformations and subsequent emergence of separate transport vesicles [126]. The induction of a membrane curvature is also an example of the damaging impact of amyloidogenic proteins on membranes [127]. The Aβ(25–35) peptide and lipid co-localization in lipid membranes may prove to represent a key factor in the mechanism of morphological reorganization induced by Aβ(25–35).

Solid-state ^{31}P NMR spectroscopy and coarse-grained molecular dynamics (CG MD) simulations provided an excellent basis to study the overall lipid–protein arrangement, including a specific Aβ(25–35) peptide localization in the lipid membranes of discs and SUVs [128]. The ^{31}P NMR spectroscopy detects a signal from phosphorus nuclei comprised in the phosphate group of lipids and reveals changes in the chemical shift. Chemical shift anisotropy of the ^{31}P nucleus is relatively high, which allows studying lipid membrane structures, various lipid phases and membrane thermodynamic states [129, 130]. It was shown that disc-forming lipid mem-

branes with incorporated Aβ(25–35) demonstrate magnetic alignment in the NMR spectrometer, resulting in the emergence of sample's anisotropy (Figure 5) [128]. Namely, the non-zero resonance lines (anisotropic phase of the sample) in the ^{31}P NMR spectra are associated with magnetic alignment of discs oriented with the normal of the lipid bilayer perpendicular to the direction of magnetic field, whereas the emergence of the isotropic phase (at 0 ppm) may be attributed to SUVs. Upon heating, the increasing alignment of discs improves disclosing the well-resolved lines, thanks to which it is possible to unravel the lipid arrangement of the discs. Two pronounced peaks corresponding to the anisotropic phase are attributed to the lipids located in the flat bilayered part of the disc (≈ -13 ppm) and those that cover the round disc edge (≈ -9 ppm).


Figure 5. The ^{31}P NMR spectra of DPPC+Aβ(25–35) systems recorded upon gradual heating through T_m of DPPC lipids with subsequent sample equilibration at $T = 50°$C for 15 h in NMR spectrometer. The isotropic phase at 0 ppm corresponds to SUVs undergoing fast isotropic motions, whereas the anisotropic phase at non-zero resonances is associated with magnetically aligned discs. Adapted from [128].

It is worth noting that there are conventionally two types of discoidal membrane nanoobjects discussed in literature: bicelles [88, 131, 132] and nanodiscs [133–135]. Being known for the ability to orient in magnetic fields because of their negative anisotropy of magnetic susceptibility, bicelles and nanodiscs are very important tools to study the lipid membrane and protein properties in a wide range of various external conditions [136, 137]. A bicelle usually consists of a mixture of short-chain and long-chain lipids, where short-chain lipids construct half-torus of a discoidal structure and cover the hydrophobic part of a lipid bilayer consisting of long-chain lipids. An alternative to bicelles is provided by nanodiscs where the half-torus is composed exclusively of a long protein or polymer that emerges in a form of belt around the discoidal structure comprising single-type lipids.

The presented NMR spectra corresponding to the anisotropic phase are incompatible with those of nanodiscs oriented in a magnetic field, but they are typical to the NMR spectra of aligned bicelles. However, neither of the arrangements is supposed to apply directly to the system of discoidal objects that emerged as a result of Aβ(25–35)-triggered membrane destabilization, since they include only single-type lipids and short peptides. Due to this

composition, they may be described as systems similar structurally to bicelles (i.e., bicelle-like structures — BLSs), in which lipids of the same type are situated both in the bilayered part and at the edges of BLSs. This would however represent an unstable combination. The explanation of the stable discoidal shape then lays in a specific lipid–peptide arrangement at the edges of BLSs. The perimeter of BLSs consists of the lipid–peptide mixture that prevents the interaction of water molecules with the membrane hydrophobic part (Figure 6*a*) [128].


Figure 6. *a*) The 2D sketch displaying geometrical parameters of the BLS in cross-section and the lipid–peptide arrangement of the BLS. Lipid head groups are shown in blue, lipid chains are displayed in black, whereas the Aβ(25–35) molecules are displayed in red. *b*) An experimental ^{31}P NMR spectrum (black line) of magnetically aligned BLSs at 41°C [128]. The spectrum is approximated by two Lorentzian functions (red lines); blue line corresponds to the sum of the two Lorentzian functions.

Based on the presented ^{31}P NMR spectra, it is possible to obtain structural parameters of the BLSs, their characteristic sizes in particular. The integral value of intensities of the ^{31}P resonances corresponding to anisotropic phase of the sample reflects the ratio of the number of lipids situated in the bilayered part of BLSs (N_b) to that in the perimeter of BLSs (N_p). Given the ratio of peak intensities, it is possible to calculate the disk diameter. N_b and N_p are proportional to the surface area of the BLS and the area of the edges, respectively. While the surface area of BLS's flat part (S_b) represents two lipid monolayers: $S_b = N_b A_L = 2\pi R_1^2$, the surface area of BLS's perimeter (S_p) can be approximately estimated as the surface area of half-torus: $S_p = N_p A_L = 2\pi R_1 \dfrac{\pi d_L}{2} = \pi^2 R_1 d_L$, where d_L is the thickness of the DPPC lipid bilayer, $R = R_1 + \dfrac{d_L}{2}$ is the radius of BLS including lipids located on a half-torus, A_L is the area per lipid (see Figure 6*a* for the sketch). Assuming that the DPPC lipids on the BLS surface and the BLS edges have the same average A_L, the BLS's diameter ($D = 2R$) is $D = \dfrac{S_b}{S_p} \pi d_L + d_L$. The S_b/S_p ratio reflects the relative areas under the peaks in the ^{31}P NMR spectra evaluated by fitting (Figure 6*b*). Thus, considering the characteristic bilayer thickness $d_L \approx 50$ Å of the gel phase DPPC membrane [83], the calculated diameter D of BLS is ≈ 400 Å. This result is in an excellent agreement with SANS and SAXS data [84].

The NMR data may be successfully complemented by the results of CG MD simulations to obtain directly the Aβ(25–35) peptide distribution in membranes. In recent years, CG models have been able to provide approaches that allow a significant increase in the timescale of simulations [138]. Due to the grouping of individual neighboring atoms into larger units, it is possible to effectively model proteins and large lipid objects on the timescales hardly available to full-atom simulations [139]. First, it was shown by means of CG MD that the randomly distributed

lipids, Aβ(25–35) peptides, and water molecules have self-assembled spontaneously into BLSs below T_m and SUVs above T_m after microsecond timescale simulations (Figure 7) [128]. The size of BLSs and SUVs was in a good agreement with that calculated from the SANS, SAXS, and NMR experiments. Second, the round edge of the BLSs was revealed to contain not only the lipid molecules but also the Aβ(25–35) peptides, which were situated at the perimeter of BLSs predominantly. The peptide–lipid co-localization at the edge of BLS allows this peculiar shape to be maintained in the aqueous environment. Thus, one of the possible disruptive mechanisms of the Aβ(25–35) peptide may be based on the ability of Aβ(25–35) to rearrange the lipid molecules around itself, creating locally a highly curved lipid bilayer.

Figure 7. Snapshots of the CG MD simulations revealing the lipid–peptide arrangement in BLSs and SUVs, where one of the vesicles is depicted with its far part sliced through its central plane. Grey color corresponds to the lipid chains, lipid head groups are shown in blue, and Aβ(25–35) molecules are displayed in red. For the sake of better visualization, water molecules are not represented. Adapted from [128].

In the formed SUVs, Aβ(25–35) peptides appear to mix randomly with lipids within the bilayer and interact with the hydrophilic part and hydrophobic region of the membrane, as it was shown by CG MD [128]. The arrangement of SUVs reveals high curvature of the lipid bilayer with an asymmetric Aβ(25–35) peptide distribution between the outer and inner leaflets (see Figure 7). This effect is likely due to the less dense packing of lipids in the outer leaflet, which provides more space for localization of peptide molecules. The lipid head groups of the outer leaflet in highly curved membranes are known to be packed more freely compared to the head groups of the inner leaflet [140]. The Aβ(25–35) peptides are then prone to diffuse to the regions of lipid bilayers with relatively loose spacing. The data presented in this part of the review provide valuable information particularly about the distribution of Aβ(25–35) peptides within the highly curved membranes, as well as the Aβ(25–35) ability to bend the lipid bilayer and thus the reasons for stability of BLSs in water environment.

5. Effect of additives

Regulations of many cellular processes are known to be affected by the membrane composition and molecular surroundings, which may govern the fluidity and rigidity of membranes, their structural organization, and lipid–peptide interactions. However, the changes of membrane properties may result in dysfunction of mechanisms that regulate the vital activity of cells. As the onset of AD is primarily related to the peptide accumulation and elevated peptide concentrations, it is important to understand the effect of Aβ(25–35) on the membrane fluidity and vice versa. It turned out that the structure of a lipid membrane at the molecular level is

greatly influenced by Aβ(25–35) peptides incorporated in membranes of ULVs. Namely, the increase in the membrane thickness with parallel increase in the ULV size has been detected [87]. The data indicate that Aβ(25–35) molecules promote an elevated membrane rigidity. In order to control the rigidity of lipid membranes with incorporated Aβ(25–35), some widespread membrane-active additives may be used, e.g., cholesterol and melatonin molecules, or calcium ions. Introduction of charged PS lipids existing at a certain fraction in the cell membranes is also an important factor for controlling the charge within the membrane.

Melatonin is a neurohormone produced in central nervous system. It has various functions, such as regulations of a circadian rhythm, energy metabolism, and inhibition of molecular oxidation [141, 142]. Regarding AD pathogenesis, melatonin has been suggested to have a protective role against amyloid toxicity [143, 144] due to their ability to inhibit Aβ-peptide production and formation of amyloid fibrils. While concentration of melatonin decreases during aging, especially for patients suffering from AD, the data from clinical trials have documented that melatonin supplementations inhibit cognitive impairment in AD patients [141, 145].

Cholesterol is a major lipid constituent of most biological membranes reaching at least 52 mol% in myelin membranes [146]. It supports their integrity and serves as a precursor for the synthesis of several vital substances [147, 148]. Cholesterol molecules present in neuronal membranes are able to regulate various protein functions. Several studies have connected an increased risk of the onset of AD and an elevated level of cholesterol concentration [149–151], while the correlation details still remain unclear [152]. Although cholesterol has been shown to play protective roles against amyloid toxicity, such as decreased Aβ-peptide accumulation and reduced Aβ tendency to assemble into membrane calcium ion channels [153, 154], it has also been documented to support transmembrane pore formation along with increased peptide ability to incorporate into lipid membranes and bind to the membrane surface [51, 155, 156]. Interestingly, dual effect of cholesterol on the Aβ(25–35)–membrane interactions has been described: at relatively low cholesterol concentrations, the deep incorporation of the peptide is favored, while the cholesterol-rich membrane prevents the Aβ(25–35) insertion [157]. At the same time, Aβ(25–35) were found to displace cholesterol molecules into plaques lowering the cholesterol concentration in a lipid bilayer [71]. Melatonin molecules were concluded to decrease the fraction of membrane-incorporated Aβ(25–35) and to increase the amount of membrane-bound Aβ(25–35) [71], which can be explained by entropic effects due to increased membrane fluidity.

Melatonin and cholesterol are able to penetrate lipid membranes and regulate their structural and dynamic properties [36, 158–161]: cholesterol is known to increase the thickness of membranes and reduce lipid lateral diffusion by increasing membrane rigidity, while the addition of melatonin to membranes results in the opposite effect. The impact of these molecules can be explained in terms of their different localization in the lipid bilayer. Namely, the cholesterol molecule having a small hydrophilic head and a hydrophobic tail is prone to be situated within the hydrocarbon chain zone of membrane, aligning itself parallel to the normal of membrane surface. Hydrophilic melatonin molecule, on the contrary, resides readily in the lipid head group region [35]. The peptide localization in the presence of cholesterol and melatonin molecules is demonstrated by MD snapshots displayed in Figure 8*a* and Figure 8*b*, respectively. A more complex construction presented in Figure 8*c* includes the Aβ(25–35)-containing membrane loaded with both cholesterol and melatonin molecules. The system illustrates the competitive effects (membrane rigidification documented by thickness increase vs. membrane fluidization documented by thickness decrease) of cholesterol and melatonin on the structural properties of lipid membranes with Aβ(25–35) incorporated [162]. The rigidifying effect of

Figure 8. The snapshots of 100 ns MD simulations depicting the patch of DOPC lipid bilayer with initially incorporated Aβ(25–35) molecules (3 mol%) and loaded with *a)* cholesterol, *b)* melatonin, *c)* cholesterol and melatonin. Concentration of cholesterol and melatonin equals 29 mol%. Cholesterol molecules are shown in yellow, melatonin molecules in black, Aβ(25–35) peptides in pink, while lipids are represented in cyan. The numbers describe the lipid membrane thicknesses extracted from MD simulations in accordance with [162].

cholesterol on the membranes with or without peptide appears to be prevailing over the fluidizing effect of melatonin [36]. Also, the immanent localization of cholesterol and melatonin molecules is unaltered in this multicomponent system when compared to the separate systems. In addition, Aβ(25–35) peptides assume a combined localization within the hydrophobic part of bilayer, while preserving their interactions with both cholesterol and melatonin.

The electrostatic interactions are yet another factor crucial for vital activity of a cell. The important roles of such interactions in a whole range of physiological processes at the membrane–water interface and in the closest membrane surroundings cannot be overestimated. An essential role in regulating the functions and elasto-mechanical properties of membranes is therefore given to the charge as well, whether in the form of charged lipids included in the cell membranes or various ions omnipresent in outer environment. Calcium ions, whose concentrations amongst cell organelles varies from nanomolar to millimolar ranges and reaches 2 mM in extracellular space, take part directly in the mineralization and contraction of tissues, signal transduction, and protein synthesis [163–165]. The ions bind to lipid head groups, predominantly situating near phosphate groups and affect membrane structure, dynamic properties of lipids, and protein–lipid interactions [38, 166–171]. Elevated concentrations of calcium ions have also been found near the deposits of Aβ peptides in AD affected brain tissues, suggesting possibly an essential role of the ions in the onset of AD [172, 173]. There are studies revealing the ability of calcium ions to promote and accelerate formation of amyloid oligomers and fibrils [174, 175], including aggregation of Aβ peptides on the lipid membrane surface, enhancing the disruption of membranes [176, 177]. In addition, it has been shown that the presence of calcium ions improves binding of Aβ-peptide monomers to lipids [178] and blocks their insertion into membranes [179].

The negatively charged lipids, PS lipids in particular, are widespread in neuronal membranes. PS lipids are one of the substantial players in apoptosis [180]; they serve as signal molecules that provide recognition and uptake of apoptotic cells by phagocytes [181]. Emergence of strong electrostatic interactions between positively charged Aβ peptide's moieties and

negatively charged lipids has been reported repeatedly [63, 64, 68, 70, 182]. At the same time, charged lipids were shown to prevent the Aβ peptides being released from the membrane [183] or to assist the peptide aggregation resulting in Aβ oligomerization and fibrilization [184, 185]. Hence, both processes may be relevant for the development of preclinical AD stage.

The role of cholesterol and melatonin, as well as the role of different ions and membrane lipid composition, is of a great importance in understanding molecular mechanisms of associated diseases. Specifically, such molecular additives may potentially serve as a tool aimed at regulating Aβ(25–35)-triggered membrane destabilization, which leads to the membrane morphological reorganizations (ULVs–BLSs–SUVs) discussed previously [84, 128]. Thus, the control of membrane fluidity through the addition of the various additives may be attempted. Unraveling their impact on the overall structure of membranes with incorporated Aβ(25–35) molecules, three particular types of effects have been observed. First, the changes of ULV structural parameters were experimentally detected upon addition of cholesterol to the lipid membranes with incorporated Aβ(25–35) by using SANS [162]. Cholesterol affected the curvature of such membranes so that ULVs were of much larger sizes than those formed by the lipid membranes without cholesterol. The effect has been explained by the increased membrane rigidity induced by cholesterol, similar as in the case of Aβ(25–35) addition. Second, melatonin molecules and charged PS lipids were demonstrated not to contribute to the structure of membranes with embedded peptides [162, 186]: they were shown not to affect significantly either the membrane thickness or the ULV size. Finally, calcium ions in the millimolar concentration range were found to inhibit the effect of Aβ(25–35) on the elastic properties of lipid membranes resulting in decrease in ULV sizes and corresponding decrease in the membrane rigidity as revealed by SAXS and SANS experiments [87]. The MD simulations detected the deep incorporation of Aβ(25–35) molecules, which was unaffected by calcium ions addition, in the hydrophobic part of lipid membrane [87]. In addition, the Aβ(25–35) secondary structure changed partly from random coils to α-helices upon the addition of calcium ions [87]. However, all the mentioned additives were detected to neither prevent, nor stimulate the Aβ(25–35)-triggered morphological membrane reorganizations and thus the membrane disintegration driven by Aβ(25–35) molecules.

6. Summary and outlook

All the effects discussed in this review become important for understanding not only the interactions between lipids and corresponding molecular constituents in cell membranes but, more importantly, for revealing opportunities to control the structural and dynamic properties of lipid membranes. After all, membranes are at a forefront of cell function and dysfunction, defense mechanisms, or disease developments. One example that is a focus of this review is the interactions between Aβ peptides and lipid membranes at the early stage of Alzheimer's disease. We have gathered together the works that establish the amyloid cytotoxicity observable via the Aβ-triggered morphological membrane reorganizations between spherical vesicles and flat bicelle-like structures. The geometries of these morphologies and their structural arrangements indicate directly the temporal destabilization of membranes during the process of reorganization. More importantly, this effect becomes instrumental in its further exploitation for studying the possibilities to prevent the membrane destabilization via various biologically active additives. The promising examples that have been reviewed comprise the addition of cholesterol and/or melatonin for controlling the membrane elasto-mechanical characteristics, and introduction of charged lipids into the membrane or ions into surrounding environment for

controlling the electrostatic interactions. Despite the local impacts on the membrane structure and/or inner structure of Aβ peptides, all the additives discussed were found impotent in preventing the Aβ-triggered morphological membrane reorganizations and thus the membrane destabilization driven by Aβ peptides.

The Aβ-peptide hypotheses, amyloid cascade hypothesis in particular, have been helpful when designing new approaches in combating AD. Although clinical trials of many drugs battling against Aβ peptides have failed, they support the necessity to proceed with comprehensive investigations of all the Aβ-peptide mechanisms involved in the AD onset at the molecular level. Their understanding provides a starting point for new therapeutic strategies and development of specific approaches for AD treatment. Thus, the findings discussed in this review provide valuable steps in understanding the role of Aβ peptides and membrane molecular environment in the onset of AD. Since complexity of membrane surroundings and progression of AD are correlated to a great extent, the interplay between Aβ peptides and lipid membranes in the presence of various molecular influencers is far from trivial. It is a process of scrutinizing various factors that will eventually allow one to reveal conditions that are necessary for the mechanism of membrane destabilization to take place, and consequently, those that may prevent it. Inspired by membrane structural changes when adding biologically relevant additives, one may understand the mechanisms of lipid–peptide interactions and decipher the ways to govern them. Nevertheless, there is still a lot of work ahead to comprehend the foundations of the onset of AD. Initiation of future studies on the emerging challenges may contribute to new approaches aimed to prevent membrane disruption of cells by the Aβ peptides.

Acknowledgements

Author contributions

S.K.: Writing — original draft preparation, Visualization, Writing — review & editing; O.I.: Writing — review & editing; T.M.: Writing — review & editing; D.B.: Visualization, Writing — review & editing; E.D.: Visualization, Writing — review & editing; E.E.: Writing — review & editing; A.K.: Writing — review & editing; N.K.: Conceptualization, Writing — review & editing.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] M. A. DeTure, D. W. Dickson, The neuropathological diagnosis of Alzheimer's disease, Molecular Neurodegeneration 14 (2019). https://doi.org/10.1186/s13024-019-0333-5.

[2] C. P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, K. Hall, K. Hasegawa, H. Hendrie, Y. Huang, A. Jorm, C. Mathers, P. R. Menezes, E. Rimmer, M. Scazufca, Global prevalence of dementia: A Delphi consensus study, The Lancet 366 (2005) 2112–2117. https://doi.org/10.1016/S0140-6736(05)67889-0.

[3] P. T. Francis, A. M. Palmer, M. Snape, G. K. Wilcock, The cholinergic hypothesis of Alzheimer's disease: A review of progress, Journal of Neurology, Neurosurgery & Psychiatry 66 (1999). https://doi.org/10.1136/jnnp.66.2.137.

[4] B. Frost, R. L. Jacks, M. I. Diamond, Propagation of tau misfolding from the outside to the inside of a cell, Journal of Biological Chemistry 284 (2009) 12845–12852. https://doi.org/10.1074/jbc.M808759200.

[5] J. A. Hardy, G. A. Higgins, Alzheimer's disease: The amyloid cascade hypothesis, Science 256 (1992) 184–185. https://doi.org/doi:10.1126/science.1566067.

[6] J. Hardy, D. Allsop, Amyloid deposition as the central event in the aetiology of Alzheimer's disease, Trends in Pharmacological Sciences 12 (1991) 383–388. https://doi.org/10.1016/0165-6147(91)90609-V.

[7] Y. Yang, D. Arseni, W. Zhang, M. Huang, S. Lövestam, M. Schweighauser, A. Kotecha, A. G. Murzin, S. Y. Peak-Chew, J. Macdonald, I. Lavenir, H. J. Garringer, E. Gelpi, K. L. Newell, G. G. Kovacs, R. Vidal, B. Ghetti, B. Ryskeldi-Falcon, S. H. W. Scheres, M. Goedert, Cryo-EM structures of amyloid-β 42 filaments from human brains, Science 375 (2022) 167–172. https://doi.org/10.1126/science.abm7285.

[8] Y. Yang, A. G. Murzin, S. Peak-Chew, C. Franco, H. J. Garringer, K. L. Newell, B. Ghetti, M. Goedert, S. H. W. Scheres, Cryo-EM structures of Aβ40 filaments from the leptomeninges of individuals with Alzheimer's disease and cerebral amyloid angiopathy, Acta Neuropathologica Communications 11 (2023) 191. https://doi.org/10.1186/s40478-023-01694-8

[9] M. Kollmer, W. Close, L. Funk, J. Rasmussen, A. Bsoul, A. Schierhorn, M. Schmidt, C. J. Sigurdson, M. Jucker, M. Fändrich, Cryo-EM structure and polymorphism of Aβ amyloid fibrils purified from Alzheimer's brain tissue, Nature Communications 10 (2019) 4760. https://doi.org/10.1038/s41467-019-12683-8.

[10] P. B. Pfeiffer, M. Ugrina, N. Schwierz, C. J. Sigurdson, M. Schmidt, M. Fändrich, Cryo-EM analysis of the effect of seeding with brain-derived Aβ amyloid fibrils, Journal of Molecular Biology 436 (2024) 168422. https://doi.org/10.1016/j.jmb.2023.168422.

[11] B. Frieg, M. Han, K. Giller, C. Dienemann, D. Riedel, S. Becker, L. B. Andreas, C. Griesinger, G. F. Schröder, Cryo-EM structures of lipidic fibrils of amyloid-β (1–40), Nature Communications 15 (2024) 1297. https://doi.org/10.1038/s41467-023-43822-x.

[12] L. Gremer, D. Schölzel, C. Schenk, E. Reinartz, J. Labahn, R. B. G. Ravelli, M. Tusche, C. Lopez-Iglesias, W. Hoyer, H. Heise, D. Willbold, G. F. Schröder, Fibril structure of amyloid-β(1–42) by cryo-electron microscopy, Science 358 (2017) 116–119. https://doi.org/10.1126/science.aao2825.

[13] M. P. Lambert, A. K. Barlow, B. A. Chromy, C. Edwards, R. Freed, M. Liosatos, T. E. Morgan, I. Rozovsky, B. Trommer, K. L. Viola, P. Wals, C. Zhang, C. E. Finch, G. A. Krafft, W. L. Klein, Diffusible, nonfibrillar ligands derived from Aβ_{1-42} are potent central nervous system neurotoxins, Proceedings of the National Academy of Sciences 95 (1998) 6448–6453. https://doi.org/10.1073/pnas.95.11.6448.

[14] U. Sengupta, A. N. Nilson, R. Kayed, The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy, eBioMedicine 6 (2016) 42–49. https://doi.org/10.1016/j.ebiom.2016.03.035.

[15] E. Y. Hayden, D. B. Teplow, Amyloid β-protein oligomers and Alzheimer's disease, Alzheimer's Research & Therapy 5 (2013) 60. https://doi.org/10.1186/alzrt226.

[16] S. Ghosh, R. Ali, S. Verma, Aβ-oligomers: A potential therapeutic target for Alzheimer's disease, International Journal of Biological Macromolecules 239 (2023) 124231. https://doi.org/10.1016/j.ijbiomac.2023.124231.

[17] U. C. Müller, T. Deller, M. Korte, Not just amyloid: Physiological functions of the amyloid precursor protein family, Nature Reviews Neuroscience 18 (2017) 281–298. https://doi.org/10.1038/nrn.2017.29.

[18] G. Thinakaran, E. H. Koo, Amyloid precursor protein trafficking, processing, and function, Journal of Biological Chemistry 283 (2008) 29615–29619. https://doi.org/10.1074/jbc.R800019200.

[19] A. Martel, L. Antony, Y. Gerelli, L. Porcar, A. Fluitt, K. Hoffmann, I. Kiesel, M. Vivaudou, G. Fragneto, J. J. de Pablo, Membrane permeation versus amyloidogenicity: A multitechnique study of islet amyloid polypeptide interaction with model membranes, Journal of the American Chemical Society 139 (2017) 137–148. https://doi.org/10.1021/jacs.6b06985.

[20] T. Kubo, S. Nishimura, Y. Kumagae, I. Kaneko, In vivo conversion of racemized β-amyloid ([D-Ser 26]Aβ 1–40) to truncated and toxic fragments ([D-Ser 26]Aβ 25–35/40) and fragment presence in the brains of Alzheimer's patients, Journal of Neuroscience Research 70 (2002) 474–483. https://doi.org/10.1002/jnr.10391.

[21] G.-f. Chen, T.-H. Xu, Y. Yan, Y.-R. Zhou, Y. Jiang, K. Melcher, H. E. Xu, Amyloid beta: Structure, biology and structure-based therapeutic development, Acta Pharmacologica Sinica 38 (2017) 1205–1235. https://doi.org/10.1038/aps.2017.28.

[22] L. Millucci, R. Raggiaschi, D. Franceschini, G. Terstappen, A. Santucci, Rapid aggregation and assembly in aqueous solution of Aβ (25–35) peptide, Journal of Biosciences 34 (2009) 293–303. https://doi.org/10.1007/s12038-009-0033-3.

[23] A. Cardinale, M. Racaniello, S. Saladini, G. De Chiara, C. Mollinari, M. C. de Stefano, M. Pocchiari, E. Garaci, D. Merlo, Sublethal doses of β-amyloid peptide abrogate DNA-dependent protein kinase activity, Journal of Biological Chemistry 287 (2012) 2618–2631. https://doi.org/10.1074/jbc.M111.276550.

[24] R. L. Frozza, A. P. Horn, J. B. Hoppe, F. Simão, D. Gerhardt, R. A. Comiran, C. G. Salbego, A comparative study of β-amyloid peptides Aβ1–42 and Aβ25–35 toxicity in organotypic hippocampal slice cultures, Neurochemical Research 34 (2009) 295–303. https://doi.org/10.1007/s11064-008-9776-8.

[25] R. Ren, Y. Zhang, B. Li, Y. Wu, B. Li, Effect of β-amyloid (25–35) on mitochondrial function and expression of mitochondrial permeability transition pore proteins in rat hippocampal neurons, Journal of Cellular Biochemistry 112 (2011) 1450–1457. https://doi.org/10.1002/jcb.23062.

[26] J. Kang, H.-G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K.-H. Grzeschik, G. Multhaup, K. Beyreuther, B. Müller-Hill, The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature 325 (1987) 733–736. https://doi.org/10.1038/325733a0.

[27] L. Millucci, L. Ghezzi, G. Bernardini, A. Santucci, Conformations and biological activities of amyloid beta peptide 25–35, Current Protein & Peptide Science 11 (2010) 54–67. http://dx.doi.org/10.2174/138920310790274626.

[28] C. J. Pike, D. Burdick, A. J. Walencewicz, C. G. Glabe, C. W. Cotman, Neurodegeneration induced by beta-amyloid peptides in vitro: The role of peptide assembly state, The Journal of Neuroscience 13 (1993) 1676. https://doi.org/10.1523/JNEUROSCI.13-04-01676.1993.

[29] M. Naldi, J. Fiori, M. Pistolozzi, A. F. Drake, C. Bertucci, R. Wu, K. Mlynarczyk, S. Filipek, A. De Simone, V. Andrisano, Amyloid β-peptide 25–35 self-assembly and its inhibition: A model undecapeptide system to gain atomistic and secondary structure details of the Alzheimer's disease process and treatment, ACS Chemical Neuroscience 3 (2012) 952–962. https://doi.org/10.1021/cn3000982.

[30] J. Liu, J. Yang, Mitochondria-associated membranes: A hub for neurodegenerative diseases, Biomedicine & Pharmacotherapy 149 (2022) 112890. https://doi.org/10.1016/j.biopha.2022.112890.

[31] M. F. M. Sciacca, C. La Rosa, D. Milardi, Amyloid-mediated mechanisms of membrane disruption, Biophysica 1 (2021) 137–156. https://doi.org/10.3390/biophysica1020011.

[32] J. M. Sanderson, The association of lipids with amyloid fibrils, Journal of Biological Chemistry 298 (2022). https://doi.org/10.1016/j.jbc.2022.102108.

[33] T. Heimburg, Mechanical aspects of membrane thermodynamics. Estimation of the mechanical properties of lipid membranes close to the chain melting transition from calorimetry, Biochimica et Biophysica Acta (BBA) — Biomembranes 1415 (1998) 147–162. https://doi.org/10.1016/S0005-2736(98)00189-8.

[34] M. R. Krause, S. L. Regen, The structural role of cholesterol in cell membranes: From condensed bilayers to lipid rafts, Accounts of Chemical Research 47 (2014) 3512–3521. https://doi.org/10.1021/ar500260t.

[35] E. Drolle, N. Kučerka, M. I. Hoopes, Y. Choi, J. Katsaras, M. Karttunen, Z. Leonenko, Effect of melatonin and cholesterol on the structure of DOPC and DPPC membranes, Biochimica et Biophysica Acta (BBA) — Biomembranes 1828 (2013) 2247–2254. https://doi.org/10.1016/j.bbamem.2013.05.015.

[36] T. Kondela, E. Dushanov, M. Vorobyeva, K. Mamatkulov, E. Drolle, D. Soloviov, P. Hrubovčák, K. Kholmurodov, G. Arzumanyan, Z. Leonenko, N. Kučerka, Investigating the competitive effects of cholesterol and melatonin in model lipid membranes, Biochimica et Biophysica Acta (BBA) — Biomembranes 1863 (2021) 183651. https://doi.org/10.1016/j.bbamem.2021.183651.

[37] D. Uhríková, N. Kučerka, J. Teixeira, V. Gordeliy, P. Balgavy, Structural changes in dipalmi-toylphosphatidylcholine bilayer promoted by Ca^{2+} ions: A small-angle neutron scattering study, Chemistry and Physics of Lipids 155 (2008) 80–89. https://doi.org/10.1016/j.chemphyslip.2008.07.010.

[38] N. Kučerka, E. Ermakova, E. Dushanov, K. T. Kholmurodov, S. Kurakin, K. Želinská, D. Uhríková, Cation–zwitterionic lipid interactions are affected by the lateral area per lipid, Langmuir 37 (2021) 278–288. https://doi.org/10.1021/acs.langmuir.0c02876.

[39] H. Binder, O. Zschornig, The effect of metal cations on the phase behavior and hydration characteristics of phospholipid membranes, Chemistry and Physics of Lipids 115 (2002) 39–61. https://doi.org/10.1016/s0009-3084(02)00005-1

[40] H.-T. Cheng, Megha, E. London, Preparation and properties of asymmetric vesicles that mimic cell membranes, Journal of Biological Chemistry 284 (2009) 6079–6092. https://doi.org/10.1074/jbc.M806077200.

[41] T. Hornemann, Mini review: Lipids in peripheral nerve disorders, Neuroscience Letters 740 (2021) 135455. https://doi.org/10.1016/j.neulet.2020.135455.

[42] P. R. Cullis, M. J. Hope, Chapter 1: Physical properties and functional roles of lipids in membranes, in: D. E. Vance, J. E. Vance (Eds.), New Comprehensive Biochemistry, Elsevier, 1991, pp. 1–41. https://doi.org/10.1016/S0167-7306(08)60329-4.

[43] M. Söderberg, C. Edlund, K. Kristensson, G. Dallner, Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease, Lipids 26 (1991) 421–425. https://doi.org/10.1007/bf02536067.

[44] M. Martínez, I. Mougan, Fatty acid composition of human brain phospholipids during normal development, Journal of Neurochemistry 71 (1998) 2528–2533. https://doi.org/10.1046/j.1471-4159.1998.71062528.x.

[45] M. Neuringer, G. J. Anderson, W. E. Connor, The essentiality of N-3 fatty acids for the development and function of the retina and brain, Annual Review of Nutrition 8 (1988) 517–541. https://doi.org/10.1146/annurev.nu.08.070188.002505.

[46] Z. Z. Guan, M. Söderberg, P. Sindelar, C. Edlund, Content and fatty acid composition of cardiolipin in the brain of patients with Alzheimer's disease, Neurochemistry International 25 (1994) 295–300. https://doi.org/10.1016/0197-0186(94)90073-6.

[47] Y.-C. Kao, P.-C. Ho, Y.-K. Tu, I.-M. Jou, K.-J. Tsai, Lipids and Alzheimer's disease, International Journal of Molecular Sciences 21 (2020) 1505. https://doi.org/10.3390/ijms21041505.

[48] K. Simons, D. Toomre, Lipid rafts and signal transduction, Nature Reviews Molecular Cell Biology 1 (2000) 31–39. https://doi.org/10.1038/35036052.

[49] C. Fabiani, S. S. Antollini, Alzheimer's disease as a membrane disorder: Spatial cross-talk among beta-amyloid peptides, nicotinic acetylcholine receptors and lipid rafts, Frontiers in Cellular Neuroscience 13 (2019) 13:309. https://doi.org/10.3389/fncel.2019.00309.

[50] S. Grassi, P. Giussani, L. Mauri, S. Prioni, S. Sonnino, A. Prinetti, Lipid rafts and neurodegeneration: Structural and functional roles in physiologic aging and neurodegenerative diseases, Journal of Lipid Research 61 (2020) 636–654. https://doi.org/10.1194/jlr.TR119000427.

[51] V. Rudajev, J. Novotny, Cholesterol as a key player in amyloid β-mediated toxicity in Alzheimer's disease, Frontiers in Molecular Neuroscience 15 (2022) 15:937056. https://doi.org/10.3389/fnmol.2022.937056.

[52] M. Díaz, N. Fabelo, I. Ferrer, R. Marín, "Lipid raft aging" in the human frontal cortex during non-pathological aging: Gender influences and potential implications in Alzheimer's disease, Neurobiology of Aging 67 (2018) 42–52. https://doi.org/10.1016/j.neurobiolaging.2018.02.022.

[53] M. Díaz, N. Fabelo, V. Martín, I. Ferrer, T. Gómez, R. Marín, Biophysical alterations in lipid rafts from human cerebral cortex associate with increased BACE1/AβPP interaction in early stages of Alzheimer's disease, Journal of Alzheimer's Disease 43 (2015) 1185–1198. https://doi.org/10.3233/jad-141146.

[54] M. Cerasuolo, I. Di Meo, M. C. Auriemma, G. Paolisso, M. Papa, M. R. Rizzo, Exploring the dynamic changes of brain lipids, lipid rafts, and lipid droplets in aging and Alzheimer's disease, Biomolecules 14 (2024) 1362. https://doi.org/10.3390/biom14111362.

[55] A. E. Abdallah, Review on anti-Alzheimer drug development: Approaches, challenges and perspectives, RSC Advances 14 (2024) 11057–11088. https://doi.org/10.1039/D3RA08333K.

[56] M. Jung, S. Lee, S. Park, J. Hong, C. Kim, I. Cho, H. S. Sohn, K. Kim, I. W. Park, S. Yoon, S. Kwon, J. Shin, D. Lee, M. Kang, S. Go, S. Moon, Y. Chung, Y. Kim, B.-S. Kim, A therapeutic nanovaccine that generates anti-amyloid antibodies and amyloid-specific regulatory T cells for Alzheimer's disease, Advanced Materials 35 (2023) 2207719. https://doi.org/10.1002/adma.202207719.

[57] C. H. van Dyck, Anti-amyloid-β monoclonal antibodies for Alzheimer's disease: Pitfalls and promise, Biological Psychiatry 83 (2018) 311–319. https://doi.org/10.1016/j.biopsych.2017.08.010.

[58] H. Yang, S.-Y. Park, H. Baek, C. Lee, G. Chung, X. Liu, J. H. Lee, B. Kim, M. Kwon, H. Choi, H. J. Kim, J. Y. Kim, Y. Kim, Y.-S. Lee, G. Lee, S. K. Kim, J. S. Kim, Y.-T. Chang, W. S. Jung, K. H. Kim, H. Bae, Adoptive therapy with amyloid-β specific regulatory T cells alleviates Alzheimer's disease, Theranostics 12 (2022) 7668–7680. https://doi.org/10.7150/thno.75965.

[59] F. Mantile, A. Prisco, Vaccination against β-amyloid as a strategy for the prevention of Alzheimer's disease, Biology 9 (2020) 425. https://doi.org/10.3390/biology9120425.

[60] D. Lee, G. Lee, D. S. Yoon, Anti-Aβ drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease, Analyst 143 (2018) 2204–2212. https://doi.org/10.1039/C7AN02013A.

[61] K. Hou, J. Zhao, H. Wang, B. Li, K. Li, X. Shi, K. Wan, J. Ai, J. Lv, D. Wang, Q. Huang, H. Wang, Q. Cao, S. Liu, Z. Tang, Chiral gold nanoparticles enantioselectively rescue memory deficits in a mouse model of Alzheimer's disease, Nature Communications 11 (2020) 4790. https://doi.org/10.1038/s41467-020-18525-2.

[62] K. Z. Mamatkulov, H. A. Esawii, G. M. Arzumanyan, Photon and neutron-based techniques for studying membrane dynamics and protein aggregation in lipid–protein interactions, Natural Science Review 1 (2024). https://nsr-jinr.ru/index.php/nsr/article/view/20.

[63] A. Buchsteiner, T. Hauβ, S. Dante, N. A. Dencher, Alzheimer's disease amyloid-β peptide analogue alters the ps-dynamics of phospholipid membranes, Biochimica et Biophysica Acta (BBA) — Biomembranes 1798 (2010) 1969–1976. https://doi.org/10.1016/j.bbamem.2010.06.024.

[64] A. Buchsteiner, T. Hauß, N. A. Dencher, Influence of amyloid-β peptides with different lengths and amino acid sequences on the lateral diffusion of lipids in model membranes, Soft Matter 8 (2012) 424–429. https://doi.org/10.1039/C1SM06823G.

[65] S. Dante, T. Hauß, A. Brandt, N. A. Dencher, Membrane fusogenic activity of the Alzheimer's peptide Aβ(1–42) demonstrated by small-angle neutron scattering, Journal of Molecular Biology 376 (2008) 393–404. https://doi.org/10.1016/j.jmb.2007.11.076.

[66] T. Kohno, K. Kobayashi, T. Maeda, K. Sato, A. Takashima, Three-dimensional structures of the amyloid β peptide (25–35) in membrane-mimicking environment, Biochemistry 35 (1996) 16094–16104. https://doi.org/10.1021/bi961598j.

[67] R. P. Mason, J. D. Estermyer, J. F. Kelly, P. E. Mason, Alzheimer's disease amyloid β peptide 25–35 is localized in the membrane hydrocarbon core: X-ray diffraction analysis, Biochemical and Biophysical Research Communications 222 (1996) 78–82. https://doi.org/10.1006/bbrc.1996.0699.

[68] S. Dante, T. Hauss, N.A. Dencher, Insertion of externally administered amyloid β peptide 25–35 and perturbation of lipid bilayers, Biochemistry 42 (2003) 13667–13672. https://doi.org/10.1021/bi035056v.

[69] A. K. Smith, D. K. Klimov, Binding of cytotoxic Aβ25–35 peptide to the dimyristoylphosphatidylcholine lipid bilayer, Journal of Chemical Information and Modeling 58 (2018) 1053–1065. https://doi.org/10.1021/acs.jcim.8b00045.

[70] E. Terzi, G. Hoelzemann, J. Seelig, Alzheimer β-amyloid peptide 25–35: Electrostatic interactions with phospholipid membranes, Biochemistry 33 (1994) 7434–7441. https://doi.org/10.1021/bi00189a051.

[71] H. Dies, L. Toppozini, M. C. Rheinstädter, The interaction between amyloid-β peptides and anionic lipid membranes containing cholesterol and melatonin, PLOS ONE 9 (2014) e99124. https://doi.org/10.1371/journal.pone.0099124.

[72] I. Ermilova, A. P. Lyubartsev, Modelling of interactions between Aβ(25–35) peptide and phospholipid bilayers: Effects of cholesterol and lipid saturation, RSC Advances 10 (2020) 3902–3915. https://doi.org/10.1039/C9RA06424A.

[73] T.-L. Lau, J. D. Gehman, J. D. Wade, K. Perez, C. L. Masters, K. J. Barnham, F. Separovic, Membrane interactions and the effect of metal ions of the amyloidogenic fragment Aβ(25–35) in comparison to Aβ(1–42), Biochimica et Biophysica Acta (BBA) — Biomembranes 1768 (2007) 2400–2408. https://doi.org/10.1016/j.bbamem.2007.05.004.

[74] H.-H. G. Tsai, J.-B. Lee, Y.-C. Shih, L. Wan, F.-K. Shieh, C.-Y. Chen, Location and conformation of amyloid β(25–35) peptide and its sequence-shuffled peptides within membranes: Implications for aggregation and toxicity in PC12 cells, ChemMedChem 9 (2014) 1002–1011. https://doi.org/10.1002/cmdc.201400062.

[75] A. Cuco, A. P. Serro, J. P. Farinha, B. Saramago, A. G. da Silva, Interaction of the Alzheimer Aβ(25–35) peptide segment with model membranes, Colloids and Surfaces B: Biointerfaces 141 (2016) 10–18. https://doi.org/10.1016/j.colsurfb.2016.01.015.

[76] M. S. Saponetti, M. Grimaldi, M. Scrima, C. Albonetti, S. L. Nori, A. Cucolo, F. Bobba, A. M. D'Ursi, Aggregation of Aβ(25–35) on DOPC and DOPC/DHA bilayers: An atomic force microscopy study, PLOS ONE 9 (2015) e115780. https://doi.org/10.1371/journal.pone.0115780.

[77] J. Tang, R. J. Alsop, M. Backholm, H. Dies, A.-C. Shi, M. C. Rheinstädter, Amyloid-β_{25-35} peptides aggregate into cross-β sheets in unsaturated anionic lipid membranes at high peptide concentrations, Soft Matter 12 (2016) 3165–3176. https://doi.org/10.1039/C5SM02619A.

[78] A. Khondker, R. J. Alsop, S. Himbert, J. Tang, A.-C. Shi, A. P. Hitchcock, M. C. Rheinstädter, Membrane-modulating drugs can affect the size of amyloid-β_{25-35} aggregates in anionic membranes, Scientific Reports 8 (2018) 12367. https://doi.org/10.1038/s41598-018-30431-8.

[79] C. Peters, D. Bascuñán, C. Opazo, L. G. Aguayo, Differential membrane toxicity of amyloid-β fragments by pore forming mechanisms, Journal of Alzheimer's Disease 51 (2016) 689–699. https://doi.org/10.3233/jad-150896.

[80] M.-c. A. Lin, B. L. Kagan, Electrophysiologic properties of channels induced by Aβ_{25-35} in planar lipid bilayers, Peptides 23 (2002) 1215–1228. https://doi.org/10.1016/S0196-9781(02)00057-8.

[81] C. Di Scala, H. Chahinian, N. Yahi, N. Garmy, J. Fantini, Interaction of Alzheimer's β-amyloid peptides with cholesterol: Mechanistic insights into amyloid pore formation, Biochemistry 53 (2014) 4489–4502. https://doi.org/10.1021/bi500373k.

[82] N. Kandel, J. O. Matos, S. A. Tatulian, Structure of amyloid β_{25-35} in lipid environment and cholesterol-dependent membrane pore formation, Scientific Reports 9 (2019) 2689. https://doi.org/10.1038/s41598-019-38749-7.

[83] J. F. Nagle, S. Tristram-Nagle, Structure of lipid bilayers, Biochimica et Biophysica Acta 1469 (2000) 159–195. https://doi.org/10.1016/s0304-4157(00)00016-2.

[84] O. Ivankov, T. N. Murugova, E. V. Ermakova, T. Kondela, D. R. Badreeva, P. Hrubovčák, D. Soloviov, A. Tsarenko, A. Rogachev, A. I. Kuklin, N. Kučerka, Amyloid-beta peptide (25–35) triggers a reorganization of lipid membranes driven by temperature changes, Scientific Reports 11 (2021) 21990. https://doi.org/10.1038/s41598-021-01347-7.

[85] N. Kučerka, J. Pencer, J. N. Sachs, J. F. Nagle, J. Katsaras, Curvature effect on the structure of phospholipid bilayers, Langmuir 23 (2007) 1292–1299. https://doi.org/10.1021/la062455t.

[86] H. Schmiedel, L. Almásy, G. Klose, Multilamellarity, structure and hydration of extruded POPC vesicles by SANS, European Biophysics Journal 35 (2006) 181–189. https://doi.org/10.1007/s00249-005-0015-9.

[87] S. Kurakin, O. Ivankov, E. Dushanov, T. Murugova, E. Ermakova, S. Efimov, T. Mukhametzyanov, S. Smerdova, V. Klochkov, A. Kuklin, N. Kučerka, Calcium ions do not influence the Aβ(25–35) triggered morphological changes of lipid membranes, Biophysical Chemistry 313 (2024) 107292. https://doi.org/10.1016/j.bpc.2024.107292.

[88] M. N. Triba, D. E. Warschawski, P. F. Devaux, Reinvestigation by phosphorus NMR of lipid distribution in bicelles, Biophysical Journal 88 (2005) 1887–1901. https://doi.org/10.1529/biophysj.104.055061.

[89] S. Mahabir, D. Small, M. Li, W. Wan, N. Kučerka, K. Littrell, J. Katsaras, M.-P. Nieh, Growth kinetics of lipid-based nanodiscs to unilamellar vesicles — A time-resolved small angle neutron scattering (SANS) study, Biochimica et Biophysica Acta (BBA) — Biomembranes 1828 (2013) 1025–1035. https://doi.org/10.1016/j.bbamem.2012.11.002.

[90] D. Otten, L. Löbbecke, K. Beyer, Stages of the bilayer-micelle transition in the system phosphatidylcholine-C12E8 as studied by deuterium- and phosphorous-NMR, light scattering, and calorimetry, Biophysical Journal 68 (1995) 584–597. https://doi.org/10.1016/S0006-3495(95)80220-1.

[91] S. S. Funari, B. Nuscher, G. Rapp, K. Beyer, Detergent-phospholipid mixed micelles with a crystalline phospholipid core, Proceedings of the National Academy of Sciences 98 (2001) 8938–8943. https://doi.org/10.1073/pnas.161160998.

[92] C. Dargel, Y. Hannappel, T. Hellweg, Heating-induced DMPC/glycyrrhizin bicelle-to-vesicle transition: A X-ray contrast variation study, Biophysical Journal 118 (2020) 2411–2425. https://doi.org/10.1016/j.bpj.2020.03.022.

[93] C. Dargel, L. H. Moleiro, A. Radulescu, T. J. Stank, T. Hellweg, Decomposition of mixed DMPC-aescin vesicles to bicelles is linked to the lipid's main phase transition: A direct evidence by using chain-deuterated lipid, Journal of Colloid and Interface Science 679 (2025) 209–220. https://doi.org/10.1016/j.jcis.2024.10.074.

[94] E. J. Dufourc, J.-F. Faucon, G. Fourche, J. Dufourcq, T. Gulik-Krzywicki, M. le Maire, Reversible disc-to-vesicle transition of melittin-DPPC complexes triggered by the phospholipid acyl chain melting, FEBS Letters 201 (1986) 205–209. https://doi.org/10.1016/0014-5793(86)80609-3.

[95] J. Dufourcq, J.-F. Faucon, G. Fourche, J.-L. Dasseux, M. Le Maire, T. Gulik-Krzywicki, Morphological changes of phosphatidylcholine bilayers induced by melittin: Vesicularization, fusion, discoidal particles, Biochimica et Biophysica Acta (BBA) — Biomembranes 859 (1986) 33–48. https://doi.org/10.1016/0005-2736(86)90315-9.

[96] T. Pott, E. J. Dufourc, Action of melittin on the DPPC-cholesterol liquid-ordered phase: A solid state ^{2}H- and ^{31}P-NMR study, Biophysical Journal 68 (1995) 965–977. https://doi.org/10.1016/S0006-3495(95)80272-9.

[97] T. Pott, M. Paternostre, E. J. Dufourc, A comparative study of the action of melittin on sphingomyelin and phosphatidylcholine bilayers, European Biophysics Journal 27 (1998) 237–245. https://doi.org/10.1007/s002490050130.

[98] T. Wang, M. Hong, Investigation of the curvature induction and membrane localization of the influenza virus M2 protein using static and off-magic-angle spinning solid-state nuclear magnetic resonance of oriented bicelles, Biochemistry 54 (2015) 2214–2226. https://doi.org/10.1021/acs.biochem.5b00127.

[99] C. Anada, K. Ikeda, A. Egawa, T. Fujiwara, H. Nakao, M. Nakano, Temperature- and composition-dependent conformational transitions of amphipathic peptide–phospholipid nanodiscs, Journal of Colloid and Interface Science 588 (2021) 522–530. https://doi.org/10.1016/j.jcis.2020.12.090.

[100] Y. Miyazaki, W. Shinoda, Cooperative antimicrobial action of melittin on lipid membranes: A coarse-grained molecular dynamics study, Biochimica et Biophysica Acta (BBA) — Biomembranes 1864 (2022) 183955. https://doi.org/10.1016/j.bbamem.2022.183955.

[101] S. J. Soscia, J. E. Kirby, K. J. Washicosky, S. M. Tucker, M. Ingelsson, B. Hyman, M. A. Burton, L. E. Goldstein, S. Duong, R. E. Tanzi, R. D. Moir, The Alzheimer's disease-associated amyloid β-protein is an antimicrobial peptide, PLOS ONE 5 (2010) e9505. https://doi.org/10.1371/journal.pone.0009505.

[102] A. Surguchov, α-Synuclein and mechanisms of epigenetic regulation, Brain Sciences 13 (2023) 150. https://doi.org/10.3390/brainsci13010150.

[103] J. F. Nagle, Theory of the main lipid bilayer phase transition, Annual Review of Physical Chemistry 31 (1980) 157–196. https://doi.org/10.1146/annurev.pc.31.100180.001105.

[104] R. Koynova, M. Caffrey, Phases and phase transitions of the phosphatidylcholines, Biochimica et Biophysica Acta 1376 (1998) 91–145. https://doi.org/10.1016/s0304-4157(98)00006-9.

[105] R. Koynova, B. Tenchov, Phase transitions and phase behavior of lipids, in: G. C. K. Roberts (Ed.), Encyclopedia of Biophysics, Springer, Berlin, Heidelberg, 2013, pp. 1841–1854. https://doi.org/10.1007/978-3-642-16712-6_542.

[106] W. J. Sun, S. Tristram-Nagle, R. M. Suter, J. F. Nagle, Structure of the ripple phase in lecithin bilayers, Proceedings of the National Academy of Sciences 93 (1996) 7008–7012. https://doi.org/10.1073/pnas.93.14.7008.

[107] T. Heimburg, A model for the lipid pretransition: Coupling of ripple formation with the chain-melting transition, Biophysical Journal 78 (2000) 1154–1165. https://doi.org/10.1016/S0006-3495(00)76673-2.

[108] K. Akabori, J. F. Nagle, Structure of the DMPC lipid bilayer ripple phase, Soft Matter 11 (2015) 918–926. https://doi.org/10.1039/C4SM02335H.

[109] M. Davies, A.D. Reyes-Figueroa, A. A. Gurtovenko, D. Frankel, M. Karttunen, Elucidating lipid conformations in the ripple phase: Machine learning reveals four lipid populations, Biophysical Journal 122 (2023) 442–450. https://doi.org/10.1016/j.bpj.2022.11.024.

[110] M. Yoda, T. Miura, H. Takeuchi, Non-electrostatic binding and self-association of amyloid β-peptide on the surface of tightly packed phosphatidylcholine membranes, Biochemical and Biophysical Research Communications 376 (2008) 56–59. https://doi.org/10.1016/j.bbrc.2008.08.093.

[111] D. M. Walsh, D. M. Hartley, Y. Kusumoto, Y. Fezoui, M. M. Condron, A. Lomakin, G. B. Benedek, D. J. Selkoe, D. B. Teplow, Amyloid beta-protein fibrillogenesis: Structure and biological activity of protofibrillar intermediates, Journal of Biological Chemistry 274 (1999) 25945–25952. https://doi.org/10.1074/jbc.274.36.25945.

[112] M. D. Kirkitadze, M. M. Condron, D. B. Teplow, Identification and characterization of key kinetic intermediates in amyloid β-protein fibrillogenesis, Edited by F. Cohen, Journal of Molecular Biology 312 (2001) 1103–1119. https://doi.org/10.1006/jmbi.2001.4970.

[113] E. Khayat, D. K. Klimov, A. K. Smith, Phosphorylation promotes Aβ25–35 peptide aggregation within the DMPC bilayer, ACS Chemical Neuroscience 11 (2020) 3430–3441. https://doi.org/10.1021/acschemneuro.0c00541.

[114] E. Khayat, C. Lockhart, B. M. Delfing, A. K. Smith, D. K. Klimov, Met35 oxidation hinders Aβ25–35 peptide aggregation within the dimyristoylphosphatidylcholine bilayer, ACS Chemical Neuroscience 12 (2021) 3225–3236. https://doi.org/10.1021/acschemneuro.1c00407.

[115] K. J. Korshavn, A. Bhunia, M. H. Lim, A. Ramamoorthy, Amyloid-β adopts a conserved, partially folded structure upon binding to zwitterionic lipid bilayers prior to amyloid formation, Chemical Communications 52 (2016) 882–885. https://doi.org/10.1039/C5CC08634E.

[116] H. Fatafta, B. Kav, B. F. Bundschuh, J. Loschwitz, B. Strodel, Disorder-to-order transition of the amyloid-β peptide upon lipid binding, Biophysical Chemistry 280 (2022) 106700. https://doi.org/10.1016/j.bpc.2021.106700.

[117] P. T. Lansbury, Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease, Proceedings of the National Academy of Sciences 96 (1999) 3342–3344. https://doi.org/10.1073/pnas.96.7.3342.

[118] M.-A. Sani, F. Separovic, How membrane-active peptides get into lipid membranes, Accounts of Chemical Research 49 (2016) 1130–1138. https://doi.org/10.1021/acs.accounts.6b00074.

[119] H. M. Brothers, M. L. Gosztyla, S. R. Robinson, The physiological roles of amyloid-β peptide hint at new ways to treat Alzheimer's disease, Frontiers in Aging Neuroscience 10 (2018). https://doi.org/10.3389/fnagi.2018.00118.

[120] H. A. Pearson, C. Peers, Physiological roles for amyloid β peptides, The Journal of Physiology 575 (2006) 5–10. https://doi.org/10.1113/jphysiol.2006.111203.

[121] A. E. Roher, C. L. Esh, T. A. Kokjohn, E. M. Castaño, G. D. Van Vickle, W. M. Kalback, R. L. Patton, D. C. Luehrs, I. D. Daugs, Y.-M. Kuo, M. R. Emmerling, H. Soares, J. F. Quinn, J. Kaye, D. J. Connor, N. B. Silverberg, C. H. Adler, J. D. Seward, T. G. Beach, M. N. Sabbagh, Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease, Alzheimer's & Dementia 5 (2009) 18–29. https://doi.org/10.1016/j.jalz.2008.10.004.

[122] V. Dubois, D. Serrano, S. Seeger, Amyloid-β peptide–lipid bilayer interaction investigated by supercritical angle fluorescence, ACS Chemical Neuroscience 10 (2019) 4776–4786. https://doi.org/10.1021/acschemneuro.9b00264.

[123] R. van Deventer, Y. L. Lyubchenko, Damage of the phospholipid bilayer by Aβ42 at physiologically relevant peptide concentrations, ACS Chemical Neuroscience (2024). https://doi.org/10.1021/acschemneuro.4c00647.

[124] A. G. Lee, How lipids affect the activities of integral membrane proteins, Biochimica et Biophysica Acta (BBA) — Biomembranes 1666 (2004) 62–87. https://doi.org/10.1016/j.bbamem.2004.05.012.

[125] P. Xie, H. Zhang, Y. Qin, H. Xiong, C. Shi, Z. Zhou, Membrane proteins and membrane curvature: Mutual interactions and a perspective on disease treatments, Biomolecules 13 (2023) 1772. https://doi.org/10.3390/biom13121772.

[126] H. T. McMahon, J. L. Gallop, Membrane curvature and mechanisms of dynamic cell membrane remodelling, Nature 438 (2005) 590–596. https://doi.org/10.1038/nature04396.

[127] N. C. Kegulian, S. Sankhagowit, M. Apostolidou, S. A. Jayasinghe, N. Malmstadt, P. C. Butler, R. Langen, Membrane curvature-sensing and curvature-inducing activity of islet amyloid polypeptide and its implications for membrane disruption, Journal of Biological Chemistry 290 (2015) 25782–25793. https://doi.org/10.1074/jbc.M115.659797.

[128] S. Kurakin, D. Badreeva, E. Dushanov, A. Shutikov, S. Efimov, A. Timerova, T. Mukhametzyanov, T. Murugova, O. Ivankov, K. Mamatkulov, G. Arzumanyan, V. Klochkov, N. Kučerka, Arrangement of lipid vesicles and bicelle-like structures formed in the presence of Aβ(25–35) peptide, Biochimica et Biophysica Acta (BBA) — Biomembranes 1866 (2024) 184237. https://doi.org/10.1016/j.bbamem.2023.184237.

[129] J. Schiller, M. Muller, B. Fuchs, K. Arnold, D. Huster, 31P NMR spectroscopy of phospholipids: From micelles to membranes, Current Analytical Chemistry 3 (2007) 283–301. http://dx.doi.org/10.2174/157341107782109635.

[130] D. Huster, Solid-state NMR spectroscopy to study protein–lipid interactions, Biochimica et Biophysica Acta (BBA) — Molecular and Cell Biology of Lipids 1841 (2014) 1146–1160. https://doi.org/10.1016/j.bbalip.2013.12.002.

[131] H. S. Cho, J. L. Dominick, M. M. Spence, Lipid domains in bicelles containing unsaturated lipids and cholesterol, The Journal of Physical Chemistry B 114 (2010) 9238–9245. https://doi.org/10.1021/jp100276u.

[132] K. Yamamoto, P. Pearcy, A. Ramamoorthy, Bicelles exhibiting magnetic alignment for a broader range of temperatures: A solid-state NMR study, Langmuir 30 (2014) 1622–1629. https://doi.org/10.1021/la404331t.

[133] F. Hagn, M. Etzkorn, T. Raschle, G. Wagner, Optimized phospholipid bilayer nanodiscs facilitate high-resolution structure determination of membrane proteins, Journal of the American Chemical Society 135 (2013) 1919–1925. https://doi.org/10.1021/ja310901f.

[134] T. Ravula, J. Kim, D.-K. Lee, A. Ramamoorthy, Magnetic alignment of polymer nanodiscs probed by solid-state NMR spectroscopy, Langmuir 36 (2020) 1258–1265. https://doi.org/10.1021/acs.langmuir.9b03538.

[135] T. Ravula, S. K. Ramadugu, G. Di Mauro, A. Ramamoorthy, Bioinspired, size-tunable self-assembly of polymer–lipid bilayer nanodiscs, Angewandte Chemie International Edition 56 (2017) 11466–11470. https://doi.org/10.1002/anie.201705569.

[136] E. J. Dufourc, Bicelles and nanodiscs for biophysical chemistry, Biochimica et Biophysica Acta (BBA) — Biomembranes 1863 (2021) 183478. https://doi.org/10.1016/j.bbamem.2020.183478.

[137] I. G. Denisov, S. G. Sligar, Nanodiscs for the study of membrane proteins, Current Opinion in Structural Biology 87 (2024) 102844. https://doi.org/10.1016/j.sbi.2024.102844.

[138] A. Liwo, C. Czaplewski, A. K. Sieradzan, A. G. Lipska, S. A. Samsonov, R. K. Murarka, Theory and practice of coarse-grained molecular dynamics of biologically important systems, Biomolecules 11 (2021) 1347. https://doi.org/10.3390/biom11091347.

[139] S. J. Marrink, A. H. de Vries, A. E. Mark, Coarse grained model for semiquantitative lipid simulations, The Journal of Physical Chemistry B 108 (2004) 750–760. https://doi.org/10.1021/jp036508g.

[140] N. Kučerka, J. F. Nagle, S. E. Feller, P. Balgavý, Models to analyze small-angle neutron scattering from unilamellar lipid vesicles, Physical Review E 69 (2004) 051903. https://doi.org/10.1103/PhysRevE.69.051903.

[141] J.-z. Wang, Z.-f. Wang, Role of melatonin in Alzheimer-like neurodegeneration, Acta Pharmacologica Sinica 27 (2006) 41–49. https://doi.org/10.1111/j.1745-7254.2006.00260.x.

[142] Y.-H. Wu, D. F. Swaab, The human pineal gland and melatonin in aging and Alzheimer's disease, Journal of Pineal Research 38 (2005) 145–152. https://doi.org/10.1111/j.1600-079X.2004.00196.x.

[143] M. Karasek, Melatonin, human aging, and age-related diseases, Experimental Gerontology 39 (2004) 1723–1729. https://doi.org/10.1016/j.exger.2004.04.012.

[144] J. M. Olcese, C. Cao, T. Mori, M. B. Mamcarz, A. Maxwell, M. J. Runfeldt, L. Wang, C. Zhang, X. Lin, G. Zhang, G. W. Arendash, Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease, Journal of Pineal Research 47 (2009) 82–96. https://doi.org/10.1111/j.1600-079X.2009.00692.x.

[145] D. K. Lahiri, D. Chen, Y.-W. Ge, S. C. Bondy, E. H. Sharman, Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex, Journal of Pineal Research 36 (2004) 224–231. https://doi.org/10.1111/j.1600-079X.2004.00121.x.

[146] R. Chrast, G. Saher, K.-A. Nave, M. H. G. Verheijen, Lipid metabolism in myelinating glial cells: Lessons from human inherited disorders and mouse models, Journal of Lipid Research 52 (2011) 419–434. https://doi.org/10.1194/jlr.R009761.

[147] A. Zampelas, E. Magriplis, New insights into cholesterol functions: A friend or an enemy?, Nutrients 11 (2019) 1645. https://doi.org/10.3390/nu11071645.

[148] J. Cipolla-Neto, F. G. Amaral, S. C. Afeche, D. X. Tan, R. J. Reiter, Melatonin, energy metabolism, and obesity: A review, Journal of Pineal Research 56 (2014) 371–381. https://doi.org/10.1111/jpi.12137.

[149] A. C. R. G. Fonseca, R. Resende, C. R. Oliveira, C. M. F. Pereira, Cholesterol and statins in Alzheimer's disease: Current controversies, Experimental Neurology 223 (2010) 282–293. https://doi.org/10.1016/j.expneurol.2009.09.013.

[150] L. Puglielli, R. E. Tanzi, D. M. Kovacs, Alzheimer's disease: The cholesterol connection, Nature Neuroscience 6 (2003) 345–351. https://doi.org/10.1038/nn0403-345.

[151] G. Di Paolo, T.-W. Kim, Linking lipids to Alzheimer's disease: Cholesterol and beyond, Nature Reviews Neuroscience 12 (2011) 284–296. https://doi.org/10.1038/nrn3012.

[152] W. G. Wood, L. Li, W. E. Müller, G. P. Eckert, Cholesterol as a causative factor in Alzheimer's disease: A debatable hypothesis, Journal of Neurochemistry 129 (2014) 559–572. https://doi.org/10.1111/jnc.12637.

[153] Y. Oku, K. Murakami, K. Irie, J. Hoseki, Y. Sakai, Synthesized Aβ42 caused intracellular oxidative damage, leading to cell death, via lysosome rupture, Cell Structure and Function 42 (2017) 71–79. https://doi.org/10.1247/csf.17006.

[154] E. Evangelisti, M. Zampagni, R. Cascella, M. Becatti, C. Fiorillo, A. Caselli, S. Bagnoli, B. Nacmias, C. Cecchi, Plasma membrane injury depends on bilayer lipid composition in Alzheimer's disease, Journal of Alzheimer's Disease 41 (2014) 289–300. https://doi.org/10.3233/jad-131406.

[155] C. Di Scala, N. Yahi, C. Lelièvre, N. Garmy, H. Chahinian, J. Fantini, Biochemical identification of a linear cholesterol-binding domain within Alzheimer's β amyloid peptide, ACS Chemical Neuroscience 4 (2013) 509–517. https://doi.org/10.1021/cn300203a.

[156] S. Devanathan, Z. Salamon, G. Lindblom, G. Gröbner, G. Tollin, Effects of sphingomyelin, cholesterol and zinc ions on the binding, insertion and aggregation of the amyloid Aβ1–40 peptide in solid-supported lipid bilayers, The FEBS Journal 273 (2006) 1389–1402. https://doi.org/10.1111/j.1742-4658.2006.05162.x.

[157] G. D'Errico, G. Vitiello, O. Ortona, A. Tedeschi, A. Ramunno, A. M. D'Ursi, Interaction between Alzheimer's Aβ(25–35) peptide and phospholipid bilayers: The role of cholesterol, Biochimica et Biophysica Acta (BBA) — Biomembranes 1778 (2008) 2710–2716. https://doi.org/10.1016/j.bbamem.2008.07.014.

[158] E. J. X. Costa, R. H. Lopes, M. T. Lamy-Freund, Permeability of pure lipid bilayers to melatonin, Journal of Pineal Research 19 (1995) 123–126. https://doi.org/10.1111/j.1600-079X.1995.tb00180.x.

[159] D. Bongiorno, L. Ceraulo, M. Ferrugia, F. Filizzola, A. Ruggirello, V. T. Liveri, Localization and interactions of melatonin in dry cholesterol/lecithin mixed reversed micelles used as cell membrane models, Journal of Pineal Research 38 (2005) 292–298. https://doi.org/10.1111/j.1600-079X.2005.00211.x.

[160] A. Filippov, G. Orädd, G. Lindblom, The effect of cholesterol on the lateral diffusion of phospholipids in oriented bilayers, Biophysical Journal 84 (2003) 3079–3086. https://doi.org/10.1016/S0006-3495(03)70033-2.

[161] A. Filippov, G. Orädd, G. Lindblom, Influence of cholesterol and water content on phospholipid lateral diffusion in bilayers, Langmuir 19 (2003) 6397–6400. https://doi.org/10.1021/la034222x.

[162] O. Ivankov, T. Kondela, E. B. Dushanov, E. V. Ermakova, T. N. Murugova, D. Soloviov, A. I. Kuklin, N. Kučerka, Cholesterol and melatonin regulated membrane fluidity does not affect the membrane breakage triggered by amyloid-beta peptide, Biophysical Chemistry 298 (2023) 107023. https://doi.org/10.1016/j.bpc.2023.107023.

[163] N. Xu, M. Francis, D. L. Cioffi, T. Stevens, Studies on the resolution of subcellular free calcium concentrations: A technological advance. Focus on "Detection of differentially regulated subsarcolemmal calcium signals activated by vasoactive agonists in rat pulmonary artery smooth muscle cells", American Journal of Physiology — Cell Physiology 306 (2014) C636–C638. https://doi.org/10.1152/ajpcell.00046.2014.

[164] J. A. Beto, The role of calcium in human aging, Clinical Nutrition Research 4 (2015) 1–8. https://doi.org/10.7762/cnr.2015.4.1.1.

[165] C. O. Brostrom, M. A. Brostrom, Calcium-dependent regulation of protein synthesis in intact mammalian cells, Annual Review of Physiology 52 (1990) 577–590. https://doi.org/10.1146/annurev.ph.52.030190.003045.

[166] N. Kučerka, E. Dushanov, K. T. Kholmurodov, J. Katsaras, D. Uhríková, Calcium and zinc differentially affect the structure of lipid membranes, Langmuir 33 (2017) 3134–3141. https://doi.org/10.1021/acs.langmuir.6b03228.

[167] S. Kurakin, O. Ivankov, V. Skoi, A. Kuklin, D. Uhríková, N. Kučerka, Cations do not alter the membrane structure of POPC — A lipid with an intermediate area, Frontiers in Molecular Biosciences 9 (2022) 926591. https://doi.org/10.3389/fmolb.2022.926591.

[168] S. A. Kurakin, E. V. Ermakova, A. I. Ivankov, S. G. Smerdova, N. Kučerka, The effect of divalent ions on the structure of bilayers in the dimyristoylphosphatidylcholine vesicles, Journal of Surface Investigation: X-Ray, Synchrotron and Neutron Techniques 15 (2021) 211–220. https://doi.org/10.1134/S1027451021020075.

[169] A. Filippov, G. Orädd, G. Lindblom, Effect of NaCl and $CaCl_2$ on the lateral diffusion of zwitterionic and anionic lipids in bilayers, Chemistry and Physics of Lipids 159 (2009) 81–87. https://doi.org/10.1016/j.chemphyslip.2009.03.007.

[170] A. Melcrová, S. Pokorna, S. Pullanchery, M. Kohagen, P. Jurkiewicz, M. Hof, P. Jungwirth, P. S. Cremer, L. Cwiklik, The complex nature of calcium cation interactions with phospholipid bilayers, Scientific Reports 6 (2016) 38035. https://doi.org/10.1038/srep38035.

[171] M. Javanainen, W. Hua, O. Tichacek, P. Delcroix, L. Cwiklik, H. C. Allen, Structural effects of cation binding to DPPC monolayers, Langmuir 36 (2020) 15258–15269. https://doi.org/10.1021/acs.langmuir.0c02555.

[172] I. Slutsky, S. Sadeghpour, B. Li, G. Liu, Enhancement of synaptic plasticity through chronically reduced Ca^{2+} flux during uncorrelated activity, Neuron 44 (2004) 835–849. https://doi.org/10.1016/j.neuron.2004.11.013.

[173] E. Smorodina, B. Kav, H. Fatafta, B. Strodel, Effects of ion type and concentration on the structure and aggregation of the amyloid peptide Aβ_{16-22}, Proteins: Structure, Function, and Bioinformatics (2023) 1–14. https://doi.org/10.1002/prot.26635.

[174] A. Itkin, V. Dupres, Y. F. Dufrêne, B. Bechinger, J.-M. Ruysschaert, V. Raussens, Calcium ions promote formation of amyloid β-peptide (1–40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease, PLOS ONE 6 (2011) e18250:18251–18210. https://doi.org/10.1371/journal.pone.0018250.

[175] K. N. Green, F. M. LaFerla, Linking calcium to Aβ and Alzheimer's disease, Neuron 59 (2008) 190–194. https://doi.org/10.1016/j.neuron.2008.07.013.

[176] M. F. M. Sciacca, D. Milardi, G. M. L. Messina, G. Marletta, J. R. Brender, A. Ramamoorthy, C. La Rosa, Cations as switches of amyloid-mediated membrane disruption mechanisms: Calcium and IAPP, Biophysical Journal 104 (2013) 173–184. https://doi.org/10.1016/j.bpj.2012.11.3811.

[177] M. F. M. Sciacca, I. Monaco, C. La Rosa, D. Milardi, The active role of Ca^{2+} ions in Aβ-mediated membrane damage, Chemical Communications 54 (2018) 3629–3631. https://doi.org/10.1039/C8CC01132J.

[178] C. Lockhart, D. K. Klimov, Calcium enhances binding of Aβ monomer to DMPC lipid bilayer, Biophysical Journal 108 (2015) 1807–1818. https://doi.org/10.1016/j.bpj.2015.03.001.

[179] S. Boopathi, R. Garduño-Juárez, Calcium inhibits penetration of Alzheimer's Aβ1–42 monomers into the membrane, Proteins: Structure, Function, and Bioinformatics 90 (2022) 2124–2143. https://doi.org/10.1002/prot.26403.

[180] S. J. Martin, C. P. Reutelingsperger, A. J. McGahon, J. A. Rader, R. C. van Schie, D. M. LaFace, D. R. Green, Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl, Journal of Experimental Medicine 182 (1995) 1545–1556. https://doi.org/10.1084/jem.182.5.1545.

[181] V. A. Fadok, D. L. Bratton, S. C. Frasch, M. L. Warner, P. M. Henson, The role of phosphatidylserine in recognition of apoptotic cells by phagocytes, Cell Death & Differentiation 5 (1998) 551–562. https://doi.org/10.1038/sj.cdd.4400404.

[182] Y. Sugiura, K. Ikeda, M. Nakano, High membrane curvature enhances binding, conformational changes, and fibrillation of amyloid-β on lipid bilayer surfaces, Langmuir 31 (2015) 11549–11557. https://doi.org/10.1021/acs.langmuir.5b03332.

[183] M. Bokvist, F. Lindström, A. Watts, G. Gröbner, Two types of Alzheimer's β-amyloid (1–40) peptide membrane interactions: Aggregation preventing transmembrane anchoring versus accelerated surface fibril formation, Journal of Molecular Biology 335 (2004) 1039–1049. https://doi.org/10.1016/j.jmb.2003.11.046.

[184] K. Matsuzaki, Physicochemical interactions of amyloid β-peptide with lipid bilayers, Biochimica et Biophysica Acta (BBA) — Biomembranes 1768 (2007) 1935–1942. https://doi.org/10.1016/j.bbamem.2007.02.009.

[185] J. Robinson, N. K. Sarangi, T. E. Keyes, Role of phosphatidylserine in amyloid-beta oligomerization at asymmetric phospholipid bilayers, Physical Chemistry Chemical Physics 25 (2023) 7648–7661. https://doi.org/10.1039/D2CP03344E.

[186] O. Ivankov, D. R. Badreeva, E. V. Ermakova, T. Kondela, T. N. Murugova, N. Kučerka, Anionic lipids modulate little the reorganization effect of amyloid-beta peptides on membranes, General Physiology and Biophysics 42 (2023) 59–66. https://doi.org/10.4149/gpb_2022052.